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Abstract 
Spectral Karyotyping analysis on human HCC has indicated previously undescribed 
frequent chromosome 19q translocations. The non-random rearrangements involving 
regional 19ql3 found have also been described in many solid tumors. In an effort to 
characterize the differential genes expression the proximity of 19ql3, we performed 
mapping study using a cDNA microarray that contains annotated cDNA clones along the 
length of chromosome 19q at an average interval of -lOOkb. A strikingly high and 
consistent down-regulation of the ATF5 gene (cyclic-AMP-dependent Activating 
Transcription Factor 5) at 19ql3.33 was suggested in 9 HCC cell lines examined (fold 
reductions ranged from 2.5 to 91). The array-derived observation was confirmed by 
quantitative RT-PCR, which further pinpointed to a repressed ATF5 expression in HCC 
tumors compared to the non-nialiganant liver (p=0.0001). In this thesis, the functional 
role of ATF5 in HCC and the possible underlying mechanism involved in its 
down-regulation were the subjects of investigations. 
Three common inactivation mechanisms including somatic mutation, copy loss and 
promoter hypermethylation were studied in HCC cell lines that display reduced ATF5 
I 
expressions. By sequencing analysis of the 4.7kb genomic sequence of ATF5, only a 
silent mutation (CTC^'" CTT^'") was found in one case, Hep3B. FISH analysis, on 
the other hand, revealed copy number loss of the ATF5 gene in 11/18 (61%) cell lines. In 
5-Aza-2，-deoxycytidine treatment of cell lines, restoration of ATF5 expression was 
indicated in 3/6 (50%) cell lines. This suggested that epigenetic control might be a 
potential mechanism in the ATF5 down-regulation. In the promoter region of ATF5, 2 
CpG islands were found. When compared to normal livers, methylation specific PGR 
and bisulfite sequencing indicated no change in methylation index in CpG island 2， 
which is closest to the ATF5 transcription start site. Examination of methylation status of 
CpG island 1 by bisulfite sequencing, on the other hand, indicated an increased in 
methylation index in 9/18 (50%) cell lines. In summary, studies on inactivating 
mechanisms suggested that copy number loss and promoter hypermethylation of CpG 
island 1 as 2 likely mechanisms involved in the down-regulations of ATF5 in HCC. 
In functional examinations of ATF5, transient and stable transfections of ATF5 into 
non-expressing HCC cell lines indicated growth suppression by 30-50% in response to 
ATF5 ectopic expression. Furthermore, a decreased tumorigenecity and delayed 
xenograft growth were demonstrated in ATF5 stably transfected Hep3B xenograft. The 
differential genes expression that underlies the functional effect of ATF5 observed was 
examined by microarray analysis. A distinct dendrogram of ATF5 transfected cells 
from control vector was indicated from cluster analysis of 112 differential expressed 
genes. Based on the 112 genes obtained, OntoPath analysis indicated 3 pathways that 
could be potentially modulated by ATF5. These included Focal Adhesion, MAPK 
signaling pathway and Regulation of actin cytoskeleton. Further analysis on the 
II 
promoter region of differential expressed genes showed 4 genes that contained the ATF 
consensus binding sequence [TGACGT(C/A)(G/A)], all of which also were 
down-regulated in response to ATF5 ectopic expression. The Id-1 gene exhibited this 
consensus sequence closest to the transcription start site and hence was further 
investigated. An inverse correlation of Id-1 expression was found in relation to the 
expression of ATF5 (尸-0.399; p=0.019). This suggested that Id-1 might be an 
immediate downstream target of ATF5 and that ATF5 might act as a transcription 
repressor in HCC. 
In conclusion, findings from this thesis support a tumor suppressive role of ATF5 in 
the development of HCC, and provide basis for further downstream characterizations of 














在細胞系Hep3B中發現序列變異但是對表型卻沒有影響(CTCieu + CTT^^")。而在營光 
原位雜交技術分析中，有11/18(61%)的細胞系出現ATF5基因複製數目減少。另一方 
















3個通路可能是由ATF5調控的’分別是Focal Adhesion ’ MAPK signaling pathway和 
Regulation of actin cytoskeleton °進一步分析有明顯表達差異的基因的啓動子，我們發 
現了其中4個基因具有ATF結合序列[TGACGT(C/A)(G/A)]，然而他們的表達水平在 
受到ATF5表達水平提高的影響下都有顯注地降低。其中Id-1的ATF結合序列最接近 
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Hepatocellular carcinoma (HCC) is a highly malignant tumor that accounts for more 
than 95% of primary malignancies that originate from the liver. HCC causes over one 
million deaths annually worldwide. The prognosis for HCC patients is often poor since 
no symptoms of the disease can be observed at the early stages. When symptoms present 
such as abdominal pain and liver failure, patients are often at the advanced metastatic 
stage where curative surgery are usually not applicable. 
1.2 Epidemiology 
HCC is the fifth most common cancer worldwide (Michielsen et al. 2005). It is the 
third and the sixth leading cause of global cancer-related death in male and female 
respectively (Figure 1.1) The estimated annual incidence of new cases is as high as over 
500,000 with a median patient survival of less than lyr (J. Ferlay 2004; Montalto et al. 
2002). HCC is also known to exhibit preferential geographic distribution where it is 
prevalent in China, Southeast Asia and Sub-saharan Africa. An incidence of >50 cases 
per 100,000 per annum was also indicated in these regions (Figure 1.2). 
In Hong Kong, HCC is the fourth most common malignancy and is the third leading 
cause of cancer mortality (HK Cancer registry 2003) (Figure 1.3). It is found that HCC 
occurs more commonly in males than females with a male to female ratio of 4.0 to 1.0 































































































































































































































































































Incidence of Liver cancer: ASR (World)-Mdle (All ages) 
• < 3.6 • < 5.0 < 8.  • < 18.4 • < 98.9 
GLQBOCAN 202 
Incidence of Liver cancer: ASR (World)-Female (All ages) f p 
• < 1.7 I < 2.5 < 4.0 • < 7.2 • < 57.3 
GLQBOCAN 202 
Figure 1.2 Worldwide distribution of liver cancer incidence estimated for year 2002 
Figure adapted from (J. Ferlay, 2004) 
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1.3 Etiological Factors 
There are several etiological factors closely associated with HCC development. They 
are viral hepatitis infections, dietary aflatoxin exposure, alcohol abuse and liver cirrhosis. 
It is due to the geographic prevalence of viral hepatitis infection and dietary aflatoxin 
exposure that HCC is prevalent in countries such as China, Japan, Southeast Asia and 
Africa. 
1.3.1 Viral Hepatitis Infection 
Hepatitis B virus (HBV) and hepatitis C virus (HCV) are the major etiologic factors 
for HCC development. These viruses are also known as the hepatotrophic viruses since 
they primarily attack the liver. Hepatotrophic viruses primarily damage the liver because 
the proteins on their surface are more specific to the receptors on the surfaces of liver 
cells. When suffering from acute viral hepatitis, symptoms of anorexia, vomiting, dark 
brown urine, light color stool, jaundice, irritating itching of the skin, fever, liver 
enlargement and abdominal pain will appear in the infected individual. 
In order to replicate, hepatitis virus must reside in living hepatocytes and use the 
metabolic process of host cells to manufacture proteins necessary for its replication. This 
hepatitis replication process is not cytotoxic. However, once the host immune system 
detected that presence of hepatitis virus in the hepatocytes, the T and B lymphocytes are 
stimulated and will directly attack the infected hepatocytes with antibodies against the 
virus secreted. As a result, hepatocellular necrosis occurs and the proliferation of 
hepatocytes is triggered. Furthermore, antigen-nonspecific inflammatory response was 
also induced (Ganem et al. 2004). During inflammation, cytotoxic chemicals and 
6 
substances are secreted, such as tumor necrosis factor (TNF) and free radicals, which can 
cause oxidative DNA damage (Hagen et al. 1994). Furthermore, liver will develop 
cirrhosis in response to a prolonged period of inflammation. These repetitive processes of 
viral infection, hepatocellular necrosis and proliferation and inflammation are the 
characteristics of chronic viral hepatitis in which together they can facilitate development 
of HCC. 
1.3.1.1 Hepatitis B Virus (HBV) 
People can be infected with HBV perinatally or through percutaneous contact with 
infected blood or body fluids. There are about 2 billion people infected with HBV and 
360 million suffering from chronic HBV infection worldwide. HBV infection is 
prevalent in Southeast Asia, China, and Africa, where the incidence of HCC is also 
highest worldwide (Lemon et al. 2000). It was suggested that individual with chronic 
HBV infection and induced cirrhosis will develop HCC at 1000 times risk higher than 
those non-carriers (Beasley et al. 1981). 
HBV was first identified in 1965 by Baruch Blumberg. It belongs to Hepadnaviridae 
family containing a 3.2kb double-stranded circular DNA (Figure 1.4). HBV contains 8 
genotypes designated from A to H, genotypes A and D are prevalent in Western countries 
while B and C are predominant in Southeast Asia and the Far East (Michielsen et al. 
2005). The DNA virus has a viral core structure containing an envelope that can protect 
HBV against host defense. It contains 4 genes, which are the S, P, C and X gene. The S 
gene codes for the viral envelope proteins (antigen) including major S-HBsAg, middle 
M-HBsAg and large L-HBsAg. The P gene codes for polymerase that is essential in HBV 
7 
replication. The C gene codes for a viral core protein (HBcAg) and a secretary protein 
HBV e antigen (HBeAg). The presence of HBeAg is indicative of the virus undergoing 
replication. The final gene, X gene, codes for hepatitis B X protein (HBx). The function 
of HBx is not fully understood, but evidences have suggested that it plays an important 
role in facilitating the development of HCC (Cougot et al. 2005). 
HBV can induce hepatocarcinogenesis through several ways including DNA damage 
and mutations caused by cytotoxic agents during inflammation and the HBV DNA 
integration into host genome. HBV DNA integrations commonly occurr in patients with 
HCC and chronic HBV infection, where the integration is believed to be able to 
dysregulate genes expression. It has been reported that HBV recurrently integrates into 
the mixed lineage leukemia 2 (MLL2) which is a potential oncogene amplified in 
leukemia, pancreatic carcinoma and glioblastoma (Huntsman et al. 1999). The MLL2 
expression was up-regulated as a result of HBV DNA integration (Tamori et al. 2005). 
Besides MLL2, integration of HBV genome into the human telomerase gene (hTERT) 
has also been reported. hTERT transcription was thought to be activated from HBV DNA 
integration, which in turn can induce telomerase activation, cellular immortalization and 
finally hepatocarcinogenesis (Horikawa et al. 2001). Furthermore, integration of HBV 
genome into host cyclin A has also been reported and an implication on cell cycle defect 
was further suggested (Wang et al. 1990). In addition to dysregulating gene expression, 
HBV DNA integration can also induce chromosomal instability causing translocation, 
chromosomal deletions and duplication insertions (Michielsen et al. 2005), all of which 
can promote HCC development. 
Apart from HBV DNA integration, viral oncoproteins HBx from HBV has been 
8 
commonly described in associations with hepatocarcinogenesis. HBx has been suggested 
to up-regulate cyclooxygenase 2 (COX-2) gene expression. COX-2 plays an important 
role in carcinogenesis and its over-expression has been reported in tumors of the colon, 
pancreas, esophagus and stomach (Cheng et al. 2004). Moreover, HBx transfection can 
also activate the N F - K B transcription with enhanced cellular invasion and metastasis 
(Chan et al. 2004a). In addition to regulating gene transcription, HBx can also interact 
with proteins such as p53, of which HBx binding to the p53 protein can antagonize its 
anti-apoptotic effect and inhibitory function on HBV replication (Feitelson et al. 1993; 
Lee et al. 1995). 
1.3.1.2 Hepatitis C Virus (HCV) 
HCV is transmitted primarily through direct exposure to blood through an opening in 
the skin or mucus membrane such as blood transfusion 
(http://www.liverfoundation.org/db/articles/1063). There are more than 170 million 
people infected with HCV worldwide and about 80% of them develop chronic hepatitis C 
(WHO 1999). HCV infection is most prevalent in Japan and Europe. Similar to HBV 
infection, HCV does not directly destroy hepatocytes. Instead, the host immune system 
against the virus will attack the hepatocytes, causing inflammation and finally cirrhosis. It 
was found that about 20% of patients with chronic hepatitis C develop cirrhosis after an 
average 20 years. When compared with HBV, HCV is more difficult to prevent since 
there is still no vaccine against HCV to date. This virus usually attacks the liver acutely, 
however, the acute disease is often mild and the symptoms unrecognized. As a result, 
chronic HCV infection develops and increases the risk of HCC development at the same 
9 
t i m e . 
HCV is linear, small positive-stranded RNA virus within the Flavivirdae family 
(Wengler et al. 1995) with 6 major genotypes designated from number 1-6 (Smith et al. 
1997)(Figure 1.5). The genome of HCV is about 9.6kb in size that encodes a polyprotein 
of about 3,010 amino acid residues. The encoded polyprotein can be cleaved by host cells 
signal peptidase associated with the cellular endoplasmic reticulum to release 3 structural 
proteins (core, El and E2) from the N-terminus of the polyprotein. Furthermore, the 
polyprotein will also be cleaved by HCV proteases to release non-structural proteins 
(NSl-3, 4A, 4B, 5A and 5B) which are essential for viral replication (Wong et al. 1998). 
Although the causative mechanism of HCV in the development of HCC is still largely 
unclear, reports have pointed to the carcinogenic properties of HCV core protein. HCV 
core protein is able to interact with ras oncogene to transform fibroblast (Ray et al. 
1996a), can suppress genes expression of p53 (Kim et al. 1994; Ray et al. 1997), can 
inhibit apoptosis (Ray et al. 1996b; Ray et al. 1998), all of which can lead to the 
enhanced development and progression of HCC (Moriya et al. 1998). 
1.3.2 Aflatoxin Exposure 
Aflatoxin is a type of mycotoxins produced by the fungal molds Aspergillus flavus 
and Aspergillus parasiticus. These molds can be found more frequently in corn, peanuts, 
cotton seed and pecans if the preservative measures were not conducted well. Aflatoxin 
contamination occurs predominantly in developing countries such as sub-Saharan Africa, 
Southeast Asia and China, where the HCC occurrence is also common. Aflatoxin B1 
(AFB-1) is the most important aflatoxin. It is a highly potent carcinogen and has been 
10 
included in the list of human carcinogens by the International Agency for Research on 
Cancer in 1988 (http://\vww.envirologix.com/artman/publish/printer 10.shtml, 
http://www.reactome.org/cgi-bin/eventbrowser?DB=gk curreiit&ID=156526&). Hotspot 
mutation of p53 caused by the AFB-1 is well recognized and occurs mainly at codon 249 
that resulted in a transversion from AGG^g to AGT^'' (Hsu et al. 1991; Ozturk 1991; 
Wong et al. 2000a). Moreover, chromosomal instability through DNA adduct formation 
with aflatoxin can induce strand breaks, micronuclei formation, sister chromatid 
exchange and unscheduled DNA synthesis (Wang et al. 1999). 
1.3.3 Alcohol Abuse 
Excessive consumption of alcohol is also an important etiologic factor of HCC 
development especially in countries with low incidence of hepatitis virus infection. HCC 
caused by alcohol abuse is prevalent in the United States and Italy where it accounts for 
32% - 45% of HCC. The risk of suffering from HCC in people that consume alcohol 
heavily for more than lOyr is 5 times higher than those who do not (Morgan et al. 2004). 
Heavy alcohol intake can cause liver cirrhosis that involved in the majority of HCC 
(Naccarato et al. 1991). Once alcoholic liver cirrhosis occurs, cessation of alcohol intake 
can no longer reduce the risk of HCC development (Lee 1966). Alcohol can also be a 
co-carcinogen with hepatitis virus that can further promote the development of HCC 
(Yoshihara et al. 1998). It was found that alcohol consumption in chronic HCV doubles 
the risk for HCC when compared with the risk in HCV alone (Morgan et al. 2004). 
11 
1.3.4 Liver Cirrhosis 
When liver tissue is chronically damaged, scarring (fibrosis) occurs. During chronic 
liver disease caused by hepatitis virus infection, alcohol abuse and hemochromatosis, 
inflammation of liver tissue occurs. Although the functions of hepatic stellate cells are not 
well understood to date, after prolonged inflammation, stimulated stellate cells will secret 
collagen. The secreted collagen will then form fibrous tissue. When the fibrous tissue 
accumulated, fibrosis in the liver can further develop into cirrhosis. About 60-90% of 
HCC cases arise from liver cirrhosis, which is also often considered as the putative 
pre-malignant lesion of HCC (Craig 1997). Figure 1.6 shows the macroscopic appearance 
of HCC arising from liver cirrhosis. 
12 
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Figure 1.4 Hepatitis B virus genomic structure 
The inner circles show the incomplete plus strand (+) and the full-length minus strand (-) 
and the 2 direct repeat sequences. The outer circles represent the 3.5，2.4, 2.1 and 0.7 kb 
mRNA transcript with variations in 5'end positions indicated as blue and red dots. Protein 
coding regions have been shown on the colored box indicated as pre SI, pre S2, S, P, X, 
pre-C and C. 
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1.4 Genetic Alterations in HCC 
The lost of integrity of the host genome underlies the development of cancers. 
Disruption of cellular pathways such as DNA repair, cell growth and cell death by the 
accumulation of activated oncogenes and inactivated tumor suppressor genes can 
resulted in uncontrolled cell growth and proliferation. Extensive molecular studies in the 
past have characterized common genomic alterations in HCC, although few candidate 
genes have been defined to date. 
1.4.1 Chromosomal Gain 
Common chromosomal gains and/or amplifications have been identified on 
chromosome Iq (38-74%), 8q (44-59%), 17q (21-31%) and 20q (20-22%) (Benbrook et 
al. 1988; Zondervan et al. 2000; Niketeghad et al. 2001; Huang et al. 2004; Luoh et al. 
2004) where 2 regions, gain of Iq and 8q, have been further implicated in the early 
carcinogenetic events. 
Chromosomal gain of Iq is most frequently observed in HCC with the smallest 
overlapping region (SOR) on Iq21-q22 further defined (Marchio et al. 1997; Qin et al. 
1999; Wong et al. 1999; Chen et al. 2000). Gain in this region can also be observed in 
lipoma-like lipo-sarcoma, nasopharyngeal carcinoma and bladder cancer (Chen et al. 
1999; Qin et al. 1999). Furthermore, it had been demonstrated in breast cancer an 
association between gains of Iq21-q22 and tumor metastasis (Engelkamp et al. 1993). 
Previous candidate gene analysis of Iq21-q22 by our group has identified several 
candidate genes over-expressions in HCC, which included Jumping translocation 
breakpoint (JTB), Src homology 2 domain containing transforming protein 1 (SHCl), 
Chaperonin containing TCPl, subunit 3 (CCT3) and Coatomer protein complex, subunit 
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alpha (COPA) (Wong et al. 2003). 
Another region where chromosomal gain frequently occurrs in HCC is 8q23-24 
(Marchio et al. 1997; Nagai et al. 1997). c-MYC located at chr.8q24 is commonly 
over-expressed in a variety of human cancers such as ovarian cancer (Chen et al. 2005), 
breast cancer (Scorilas et al. 1999) and HCC (Kawate et al. 1999). In the chronic 
hepatitis infection and cirrhotic livers but not in normal livers, over-expression of 
c-MYC in the nuclear and cytoplasm has been observed. This suggests that livers with 
c-MYC over-expression might predispose to early transcriptional changes in the liver 
carcinogenesis (Chan et al. 2004b). In metastatic HCC, higher level of c-MYC 
amplifications was detected when compared to solitary HCC, suggesting the level of 
c-MYC was also correlated with the metastatic ability of HCC cells (Wang et al. 2002). 
A role for c-MYC in liver tumorigenesis was further demonstrated when a suppression 
of c-MYC expression in HCC cells could bring about a regression of tumorigenecity 
(Shachaf et al. 2004). 
1.4,2 Chromosomal Loss 
Common chromosomal losses in HCC have been identified on chromosomes Ip 
(22-50%), 4q (36-57%), 8p (32-63%)，13q (30-56%), 16q (33-70%) and 17p (28-64%) 
(Bressac et al. 1991; Gschwend et al. 1996; Guan et al. 2000; Zondervan et al. 2000; 
Niketeghad et al. 2001). In addition to HCC, these chromosomal regional losses have 
also been found in other cancer types such as colon, lung, gastric, larynx, breast and 
prostate cancer (Emi et al. 1992; Ogunbiyi et al. 1997; Anbazhagan et al. 1998; 
Lutchman et al. 1999; Baffa et al. 2000; Yoo et al. 2004b). Genes residing on these 
regions may thus play an important role in carcinogenesis. 
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Chromosomal loss of 4q and 8p was most frequently found in HCC. It was reported 
that 4q losses were significantly correlated with the presence of HBsAg, moderate and 
poor histological grade and intrahepatic metastasis (Zhang et al. 2005). Although SOR 
has been defined to 4q21-q22 in HCC, candidate genes within this region remain to be 
identified (Marchio et al. 1997). Chr.Sp losses have been suggested not only in HCC, but 
also in bladder cancer (Adams et al. 2005), urothelial cancer (Sengelov et al. 2000), 
breast cancer (Anbazhagan et al. 1998) and prostate cancer (Crundwell et al. 1996). On 
Chr.8p, the SOR has been defined to 8p21-23 (Marchio et al. 1997; Qin et al. 1999; 
Zondervan et al. 2000; Chan et al. 2002; Zhang et al. 2005) where candidate genes such 
as Fibrinogen-like 1 (FGLl) and Deleted in Liver Cancer 1 (DLCl) on 8p22 have been 
implicated in the liver carcinogenesis. Both FGLl and DLCl were found to be 
frequently down-regulated in HCC, where a role in cell proliferation and invasion was 
suggested (Yamamoto et al. 1993; Yuan et al. 1998; Ng et al. 2000; Yan et al. 2004; Zhou 
et al. 2004). 
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1.5 Discovery of C o m m o n Activating Transcription Factor 5 (ATF5) D o w n 
regulations in HCC 
1.5.1 Chromosome 19 Aberration in HCC 
Using Spectral Karyotyping (SKY) analysis, our group has previously reported on 
the novel finding of frequent chromosome 19 structural rearrangements (-70% cases) 
(Figure 1.7) in primary HCC tumor (Wong et al. 2000b). Common chromosome 19 
aberrations have also been found in oligodendriaglioma (van den Bent 2004), gliomas 
(Chou et al. 1996; Rosenberg et al. 1996; Zhu et al. 1998)，neuroblastoma (Mora et al. 
2001) and bladder cancer (Panani et al. 2004), in which a prognostic implication of 
chromosome 19 aberration has been further suggested in oligodendriaglioma (Hartmann 
et al. 2005) and glioblastoma (Angelastro et al. 2006). Mapping analysis of Chr. 19 in 
neuroblastoma and oligodendroglialma has defined a common deleted region Chr.l9ql3 
within which putative tumor suppressor gene(s) residing on this region has been further 
speculated (Reifenberger et al. 1994; Jeuken et al. 2004). 
1.5.2 Discovery of High Frequency ofATF5 Down-regulations 
In an effort to define candidate gene(s) on chromosome 19q in HCC, transcriptional 
mapping was carried out using a high-resolution cDNA microarray. The array employed 
contained -600 cDNA clones that spanned an average interval of ~ 100Kb on Chr. 19. 
The results indicated a strikingly high and consistent down-regulations of 2 candidate 
genes, namely Activating Transcription Factor 5 {ATF5) and Acid Phosphatase 5 (ACP5) 
(Figure 1.8). Studies on ACP5 have been carried out by members of our group and 
results have been published earlier in 2005 (Chan et al. 2005). ATF5, on the other hand, 
is the subject of this thesis. 
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ATF5 is normally highly expressed in the liver (Figure 1.9)，but much repressed in 
both HCC cell lines and primary tumor as indicated by quantitative RT-PCR in earlier 
studies by members of our group (Figure 1.10). A significant reduction of ATF5 
expression in HCC compared to adjacent non-malignant liver was suggested in a cohort 
of 65 paired cases examined (p=0.0001). On the other hand, when the niRNA levels of 
ATF5 were correlated with tumor stagings, no significant difference between early and 
advanced stage HCC was suggested (Figure 1.11). Our initial analysis would imply 
ATF5 down-regulation might play a role in early carcinogenetic events. 
1.5.3 Activating Transcription Factor Family 
ATF5 belongs to the ATF/CREB family of activating transcription factors (ATF). 
ATF is a group of basic-region leucine zipper (bZIP) proteins with the consensus DNA 
binding sequence of TGACGT(C/A)(G/A). This sequence corresponds to the cAMP 
response element (CRE) that is present in many viral and cellular promoters. Proteins 
within this family can be grouped into subgroups based on the amino acid similarity, 
which included subgroups CREB，CRE-BPl, ATF3，ATF4, ATF6 and B-ATF (Table 1-1). 
The proteins within each subgroup share similarity throughout the entire protein. 
However, proteins between subgroups share only similarity within the bZIP domain (Hai 
et al. 2001). 
The function of ATF family members has been described in the regulation of genes 
expression. During gene transcription, ATF within or between subgroups can form 
homo- or hetero-dimer through the bZIP domain. The dimer can then bind to the DNA 
through the basic-motif. The formation of homo- or hetero-dimer can alter DNA binding 
specificity and transcriptional activities of the ATF, and so the regulatory ability of ATF 
20 
can be expanded. The ATF family has diverse functions involved in cell survival, 
cellular proliferation and cell cycle control. When different dimers are formed, ATF may 
serve as transcription activator or repressor. Previous studies have suggested that ATF4 
can act both as a transcriptional activator (Talukder et al. 2000) or repressor depending 
on the cellular microenvironnient (Lassot et al. 2001). 
Few ATF family members, such as ATF2, ATF3 and ATF4, have also been 
demonstrated to be involved in facilitating carcinogenesis. For examples, 
over-expression of ATF2 could induce cell growth (Huguier et al. 1998), 
down-regulation of ATF3 has been suggested in suppressing cell migration ability of 
colon cancer cell (Ishiguro et al. 2000) and up-regulation of ATF4 was associated with 
cisplatin-resistance in prostate cell line (Tanabe et al. 2003). 
ATF5 is a member of ATF4 subgroup in which they share 57% similarity over their 
bZIP domains (White et al. 2000; Morris et al. 2003). Human ATF5 locates at 
Chr.l9ql3.3 has a genomic size of 4.7kb that contains a 5'UTR and 2 exons. The 
full-length transcript of 2kb translates to 282 amino acids and a final protein size of 
30.7kDa. In the ATF5 protein, there are 2 proline rich regions that span 123-139aa and 
186-194aa, 1 basic motif that spans 210-230aa and 1 bZIP domain that spans 236-250aa 
(Figure 1.12). Previous study has suggested the role oiATF5 in differentiation control as 
a transcriptional repressor by competing for binding to CREs (Angelastro et al. 2003). 
When ATF5 expression was suppressed in neural progenitor cells and oligodendrocyte 
precursors，differentiation will occur. However, down-regulation o{ ATF5 alone was not 
sufficient to initiate differentiation, stimulation from appropriate neurotrophic factor was 
needed to induce cell differentiation (Angelastro et al. 2003; Angelastro et al. 2005; 




Figure 1.7 Chromosome 19 translocations in HCC samples 
Translocations of Chr.l9 to Chr.l7 (A) and Chr.l6 (B) are shown 
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Figure 1.9 Expression arrays of ATF5 in different tissues 
ATF5 is highly expressed in liver 
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Figure 1.10 ATF5 was down-regulated in HCC cell lines compared with normal liver (A). 
A significant repression of ATF5 was also suggested in primary HCC compared to adjacent 
non-malignant liver by paired Student's t-test (B) 
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T: HCC tumors 
TN: Paired adjacent non-malignant liver 
Figure 1.11 No significant difference in the level of ATF5 expression was suggested 
between early (T1/T2) and advanced (T3/T4) stage of HCC 
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Table 1-1 The mammlian ATF/CREB family of transcription factors 
Subgroup Members Alternative names 
CREB CREB ATF-47 
CREM 
ATFl TREB36, TCRATFl, ATF-43 
CRE-BPl CRE-BPl ATF2, HB16, TREE, TCR-ATF2, mXBP 
ATFa 
CRE-BPa 
ATF3 ATF3 LRF-1, LRG-21, CRG-5, TI-241 
JDP-2 
ATF4 ATF4 CREB2, TAXREB67, mATF4, C/ATF, mTR67 
ATFx hATF5 




Table adapted from (Hai et al. 2001) 
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Figure 1.12 A sketch showing different domains of the ATF5 protein 
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1.6 Aims of Thesis 
The novel identification of frequent ATF5 down-regulations in HCC from earlier 
studies of our laboratory has prompted the further investigations described in this thesis. 
The objectives of this thesis are: 
1. To investigate the molecular mechanism(s) that inactivates ATF5 expression in 
HCC 
> Mutational analysis by sequencing, copy number enumeration by FISH and 
investigation of promoter methylation status by methylation specific PGR and 
bisulfite sequencing on HCC cell lines were carried out 
2. To investigate the functional role of ATF5 on HCC 
> Transient and stable ectopic expression of ATF5 in HCC cell lines was 
performed. The effect of ATF5 on in-vitro cell growth and in-vivo 
tumorigenecity was examined 
3. To investigate the potential downstream pathway(s) modulated by ATF5 and 
downstream target(s) 
> CodeLink cDNA microarray was performed to determine the differentially 
expressed gene(s) after transient and stable transfection o ^ T F S in Hep3B cells 
> Analysis of microarray results was carried out to define potential candidate 
gene(s) and further correlation with ATF5 expression 
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Chapter 2 





Thiazolyl blue tetrazolium bromide (MTT) Sigma Chemical Company 
Trypan blue Gibco Invitrogen Corporation 
Dimethyl sulfoxide (DMSO) Sigma Chemical Company 
Phenol/Chloroform/isoamyl alcohol 25:24:1 (v:v:v) Gibco Invitrogen Corporation 
Trizol Gibco Invitrogen Corporation 
Agarose, regular Biowest 
Ethylenediaminetetraacetic acid (EDTA) Sigma Chemical Company 
Formamide Intergen Company 
4',6-Diamidino-2-phenylindole (DAPI) Sigma Chemical Company 
Lipofectamine 2000 Gibco Invitrogen Corporation 
Tween 20 Sigma Diagnostic 
Cy5-Streptavidin Amersham Biosciences 
Ethidium bromide Sigma Chemical Company 
40% Arcylamide/bis 29:1 Gel Solution BioRad Laboratories 
Ammonium persulfate (APS) Sigma Chemical Company 
N,N,N',N'-tetramethylethylenediamine (TEMED) Sigma Chemical Company 
O C T S A K U R A 
NaOAc Sigma Chemical Company 




25mM MgC12 Applied Biosystems 
Sephadex TM G-50 Fine Amersham Biosciences 
Hi-Di formamide Applied Biosystems 
LB broth USB 
LB agar USB 




Trichostatin A Sigma Chemical Company 
Kanamycin Sigma Chemical Company 
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2. L2 Buffers 
Buffers Company/Reagent 
Phosphate buffer saline (PBS), pH7.4 Sigma Chemical Company 
Tris acetate EDTA buffer (TAE), pH7.4 Sigma Chemical Company 
Tris borate EDTA buffer (TBE), pH7.4 Sigma Chemical Company 
Sodium chloride-sodium citrate concentrate 3M sodium chloride, 0.3M sodium citrate, 
(SSC) pH7.0 
(20X) 
TNT buffer 0.1M Tris-HCL, pH7.6, 0.15M NaCl, 
0.05% Tween 20 
TNB buffer 0.1M Tris-HCL, pH7.6, 0.15M NaCl, 
0.5% NEN blocking reagent 
IM Tris-HCL, 0.5M EDTA, dH20 water, (pH 
DNA extraction buffer 8.0) 
1 OX PCR buffer Applied Biosystems 
RQl DNase lOX Reaction Buffer Promega Corporation 
ACD solution (citrate-dextrose solution) 0.023M Citric acid, 0.045M Sodium citrate, 
0.082M Glucose 
1 OX Reaction buffer 0.5mM Tris HCl, pH8.0, 50mM MgC12, 
0.5mg/ml BSA, O.IM b-Mercaptoethanol 
Master Mix 20% Dextransulfate in 2x SSC 
2.1.3 Cell Culture 
Reagents Company 
AIM-IV Gibco Invitrogen Corporation 
DMEM Gibco Invitrogen Corporation 
Fetal calf serum (FBS) Gibco Invitrogen Corporation 
Penicillin and streptomycin Gibco Invitrogen Corporation 
Trypsin Gibco Invitrogen Corporation 
MEM Non-Essential Amino Acids Solution Gibco Invitrogen Corporation 
L-Glutamine Gibco Invitrogen Corporation 
OPTI-MEM® I Gibco Invitrogen Corporation 
Tissue culture flask (150, 75, 25 cm2) BD Labware Company 
Tissue culture flask (175 cm2) NUNC 
Tissue culture plate (96-well) BD Labware Company 
Petri-dish (100mm) BD Labware Company 
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2.1.4 Nucleic Acids 
Reagents Company 
All custom designed oligos Gibco Invitrogen Corporation 
Biotin-11 -UTP Boehringer Mannheim 
Deoxynucleotide Trisphosphate Set, PCR grade Boehringer Mannheim 
Human Cot-I DNA Gibco Invitrogen Corporation 
Salmon Testes DNA Sigma Chemical Company 
Human normal total liver RNA Ambion Inc 
Human normal total liver RNA Clontech Laboratory Inc 
Human normal total liver RNA Strategene 
1 kb Plus DNA Ladder Gibco Invitrogen Corporation 
CpGenomeTM Universal methylated DNA Chemicon 
BAC clones (RP11-510I16 and RP11-110A23) Gibco Invitrogen Corporation 




Proteinase K recombinant, PCR grade Roche Diagnostics Corporation 
RQ1 RNase-free DNase Promega Corporation 
AmpliTaq Gold DNA polymerase Applied Biosystems 
RNase Boehringer Mannheim 
Pepsin Boehringer Mannheim 
DNasel Boehringer Mannheim 
DNA polymerase usb R 
2.1.6 Equipment 
Equipment Company 
SPECTRA Rainbow v2.02 plate reader. TECAN Austria Ges.m.b.H 
CM3000-Cryostat Leica Corporation 
Leitz DM RB fluorescence microscope Leica Corporation 
GeneQuant Pharmacia Biotech 
ICYCLER IQ real time detection system BioRad Laboratories 
GenePix 4000B Array Scanner Axon Instruments 
DNA Speed Vac® DNA 110 Savant 
ABI PRISM R 3100 Genetic Analyzer Applied Biosystems 
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2.1 J Kits 
Kit Company 
QIAamp® DNA Mini Kit Qiagen, Germany 
QIAquick PGR Purification Kit Qiagen, Germany 
BigDye Terminator Cycle Sequencing Kit Applied Biosystems 
EZ DNA Methylation Kit Zymo Research 
TOPO TA Cloning® Kit Gibco Invitrogen Corporation 
QIAprep® Spin Miniprep Kit Qiagen, Germany 
SYBR Green PGR Core Reagents Kit Applied Biosystems 
Taqman PGR Core Reagent Kit Applied Biosystems 
QIAGEN® Plasmid Midi Kit Qiagen, Germany 
RNeasy Mini Kit Qiagen, Germany 
QIAGEN plasmid maxi kit Qiagen, Germany 
TaqMan® Reverse Transcription Reagents Applied Biosystems 
FastStart High Fidelity PGR system Roche 
2.1.8 Software and Web Resources ； 
Software and web resources Company / URL ‘ 
GenePix 4000B scanner Axon Instruments 
CodeLink Expression Analysis software Amersham Life Sciences 
GenBank Database http://genome.ucsc.edu/cgi-bin/hgGateway ‘ 
Primer 3 http://frodo.wi.mit.edu/cgi-bin/primer3/ 
primer3_www.cgi ‘ 
Multiple sequence alignment with hierarchical j 
clustering http://prodes.toulouse.inra.fr/multalin/ |i 
multalin.html , 
Cluster software package http://rana.lbl.gov/EisenSoftware.htni 
Treeview software http://rana.lbl.gov/EisenSoftware.htm 
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2.2 DNA EXTRACTION 
2.2.1 Cell Line 
Cells at 80% confluence were trypsinized in IX trypsin/EDTA. Cell pellet obtained 
was washed with IX PBS and lysed in 2ml extraction buffer. Proteins were digested 
with lOOul protease K (lOmg/ml) at 56°C overnight. Additional protease K at 50ul was 
added to cell lysate the following day and incubated at 56°C for further 4hr. 
Phenol/chloroform/isoamyl alcohol in ratio 25:24:1 (v:v:v) at 2ml was then added and 
the mixture was shaken for 2hr. The mixture was then centrifuged at 4,500rpm, 4°C for 
15min and the top aqueous phase layer was carefully collected. The total DNA in the 
aqueous phase were precipitated by adding 1/10 volume of 3M sodium acetate and 2.2 
volume of cold absolute ethanol. The total DNA pellet obtained was dissolved in ddHzO 
at room temperature overnight. To ensure DNA quality, a second round of DNA 
precipitation was performed. Twenty-five microliter RNase (lOmg/ml) was added to the 
total DNA extracted at 37°C for 4hr. DNA extraction by phenol/chloroform/isoamyl 
alcohol and precipitation by sodium acetate and absolute ethanol was repeated. The final 
DNA pellet obtained after centrifugation was washed with 70% cold ethanol and 
dissolved in 50-200ul ddH20 after air dried. 
2.2.2 Primary HCC 
OCT embedded normal human liver tissue was sectioned by cryostat. Sectioned 
liver tissue was washed with IX PBS for 3 times to remove all the OCT and DNA was 
extracted using QIAamp® DNA Mini Kit. After washing the liver sections with PBS, 
180ul tissue lysis buffer was added to the tissue, 20ul Protease K (20mg/ml) and 20ul 
RNase (20mg/ml) was added to digest the protein and RNA in the liver tissue. After 
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digestion at 37 °C for 4hr, a further 200ul lysis buffer was added to the liver tissue and 
200ul absolute ethanol was added to precipitate the DNA. The mixture was then 
transferred to QIAamp spin column and centrifuge for Imin at SOOOrpm. The membrane 
in the column was washed with 500ul washing buffer. Finally, 200ul ddEbO was added 
to the membrane to elute the purified DNA. 
2.2.3 Lymphocytic DNA 
Lymphocytic DNA was extracted from healthy individuals of both male and female. 
Twenty milliliter peripheral blood was collected in corning 50ml-centrifuge tube 
containing 20ml of ACD (citrate-dextrose) solution. The blood sample was then snapped 
frozen at -20°C overnight and thawed at room temperature the following day. Twenty 
milliliter blood sample was added to 20ml IX PBS and the mixture was centrifuged at 
4000rpm for 30min at room temperature. Supernatant was discarded and the pellet was 
re-suspended in 9ml ddHsO and 1ml lOX PBS. The mixture was centrifuged again at 
4000rpm for 15niin at room temperature to remove red cells debris. This process was 
repeated twice. The cell pellet was then re-suspended in 5ml extraction buffer, lOul of 
1 Omg/ml RNase was added and the mixture was incubated at room temperature for Ihr 
with gentle agitation. Thereafter, 50ul of 1 Omg/ml Proteinase K was added and 
incubated at 56°C overnight. Five milliliter of Phenol/Chloroform/Isoamyl alcohol was 
added and the mixture was mixed well for 1 Omin prior to centrifugation at 4000rpm for 
15min. The upper aqueous layer was carefully collected and 1/10 volume of 3M 
sodium acetate and 2.5 volume of cold absolute ethanol was added to precipitate the 
DNA. After centrifugation at 4000rpm for 3Omin, the DNA pellet obtained was washed 
with cold 70% ethanol and resuspended in 50-200ul ddHaO after air-dried. 
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The quantity and quality of DNA were determined by the ratio of absorbance at 
260nm and 280nm using GeneQuant pro and visualization by agarose gel 
electrophoresis before storage at -20°C until use. 
2.3 RNA EXTRACTION 
Cell lines were washed with DEPC-treated PBS and lysed with TRIZOL reagent in 
an amount of 1 ml per 1 Ocm^ culture dish surface area. The lysate obtained was snapped 
frozen at -80°C for at least 16hr. After thawing the cell lysate at room temperature, 
chloroform was added in a ratio of Trizol:Chloroform, 1:0.2. The mixture was shaken 
gently for 15 sec and was left at room temperature for 3min prior to centrifugation and 
then centrifuged at 10,000rpm for 15min at 4°C. Following phase separation, total RNA 
in the aqueous phase was carefully collected and precipitated by isopropanol in a ratio 
Trizol:Isopropanol, 2:1. Following overnight incubation, the mixture was centrifuged at 
10,000rpm for 30min at 4°C, the supernatant was discarded and the RNA pellet was 
washed once by 70% cold DEPC-ethanol. Total RNA extracted was dissolved in 
DEPC-treated ddH20. The concentration of total RNA was measured by the ratio of 
absorbance at 260nm and 280nm using GeneQuant pro and the quality of total RNA was 
determined by agarose gel electrophoresis before storage at -80°C. 
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jyj Normal Liver 
NLl NL2 NL3 
2000bp 
lOOObp 
B M HKCI- series of cell 
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• 
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500bp 
Figure 2.1 (A) 1% agarose gel electrophoresis of high molecular weight DNA 
obtained from normal livers (NL1-NL3) 
(B) 1% agarose gel electrophoresis of RNA extracted from in-house 
established HKCI-series of HCC cell lines 
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2.4 DNA SEQUENCING 
2.4.1 Polymerase Chain Reaction (PCR) 
Due to the difficulty in obtaining PCR product on ATF5 Exon 2-1,2 different PCR 
systems were employed in this project. 
First PCR system for ATF5 5，UTR, Exonl and Exon2-2: In 25ul reaction, lOOng of 
genomic DNA, 2.5ul lOX PCR buffer, 1.5ul 25mM MgCb, 0.25ul lOmM dNTP, 0.25ul 
5U/ul AmpliTaq Gold DNA polymerase and 0.5ul lOuM for each of the sense and 
anti-sense primers were added. The thermal cycling conditions were: lOmin at 95°C, 
followed by 30 amplification cycles of denaturing at 95°C for Imin, annealing at primer 
specific temperature for Imin and extension at 72°C for Imin, with a final extension of 
lOmin at 72�C. 
Second PCR system for ATF5 Exon2-l: One hundred nanogram of genomic DNA 
in 25ul reaction mix was amplified using FastStart High Fidelity PCR System, which 
contains 2ul lOX Reaction Buffer, 0.14ul Enzyme Blend, 0.4ul lOmM dNTP and 0.5ul 
lOuM for each of the sense and anti-sense primers. The thermal cycling conditions were: 
2min at 94°C，followed by 30 amplification cycles of denaturing at 94°C for 30sec, 
annealing at primer specific temperature for 30sec and extension at 72°C for Imin, with 
a final extension of lOmin at 72°C. 
For both systems, 5ul PCR product was subjected to agarose gel electrophoresis. In 
the absence of non-specific PCR products, PCR products were purified with QIAquick 
PCR Purification Kit. During PCR purification, 5X volume of binding buffer which 
binds the DNA to the membrane in column was added to PCR product, the mixture was 
transferred to a column and centrifuge at 13,200rpm for Imin. Then, the PCR product in 
the membrane of the column was washed with 750ul washing buffer and centrifuged at 
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13,200rpm for Imin. Thirty microliter ddHsO was then added to the membrane to elute 
the purified PGR product. 
2.4.2 Cycle Sequencing 
The DNA sequencing was performed using the BigDye Terminator Cycle 
Sequencing Kit. In 15ul of sequencing reaction, 5ul of purified PGR product was mixed 
with 3.22uM primer, 2.25ul Sequencing Buffer and 1.5ul Big Dye. The thermal cycling 
conditions were as follows: Imin at 96°C, followed by 30 amplification cycles of 
denaturing at 96°C for lOsec, annealing at 50°C for 5sec and extension at 60°C for 4min. 
The products were purified with Sephadex^'^ G-50 Fine column to remove 
unincorporated nucleotides. The samples were then denatured together with 8|il Hi-Di 
formamide by 95°C for 5 min and chilled on ice before running the automated ABI 
PRISM®3100 Genetic Analyzer. Figure 2.2 shows representative images of sequencing 
results. Analysis on the sequence data was performed using "Multiple sequence 




TTCCACTTTCGCCTTGGTGCCTGTC T TCGCCCAC C T G AG C 
45 50 55 60 65 70 75 80 
B. Normal Liver 
：T TCCAC TTTCGCCTTGGTGCCTGTCTTCGCCCACC T GAG C 
40 46 50 55 60 65 70 75 
Figure 2.2 A Partial sequence of ATF5 Exon 1 from Hep3B 
B Partial sequence of ATF5 Exon 1 from normal liver 
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2.5 DUAL-LABELLED FLUORESCENCE IN SITU HYBRIDIZATION 
(FISH) 
2.5.1 FISH Probe Preparation 
2.5.1.1 Preparation of Human Bacterial Artificial Chromosome (BAC) 
BAC clones RP11-510I16 (at Chr.l9ql3.3 that contains ATF5) and RP11-110A23 
(at Chr.lp31) were streaked on LB plate containing O.lmg/ml Kanamycin and incubate 
at 37°C for 16hr. Single colony was picked and cultured in LB broth with O.lmg/ml 
Ampicillin in a shaking incubator at 220 rpm for 16hr at 37°C. BAC was extracted using 
QIAGEN plasmid maxi kit. The quantity and quality of BAC was determined by 
GeneQuant pro and agarose gel electrophoresis. The FISH probes were first verified on 
normal metaphase for location and chimerism prior to cell line studies. 
2.5.1.2 Nick Translation 
Fifty microliter reaction mixture containing lug BAC DNA, 5ul lOX reaction 
buffer, 6ul 2mM dNTPs, 2ul fluorescence labeled-dUTPs, i.e. Spectrum Orange-dUTP 
(SO) or Spectrum Green-dUTP (SG), 5ul DNasel (1/250U) and lul DNA Polymerase 
(11.8U/ul) was incubated at 15�C for 4hr. The size of DNA fragments 500-1000bp for 
SO and SG after nick translation was checked by agarose gel electrophoresis. The 
reaction was stopped by adding 2.5ul 0.2M EDTA. Forty microliter Img/ml Human 
Cot-1 DNA and lul Salmon Testes DNA were then added and the whole reaction 
mixture. The BAC was precipitated by adding 1/10 volume of sodium acetate and 
2.5-times final volume of absolute ethanol. After placing at -20°C for at least 3hr, the 
DNA mixture was centrifuged at 10,000rpm, at 4°C for 30min. The BAC pellet obtained 
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was washed by cold 70% ethanol and air dried at room temperature. The BAC probe was 
finally dissolved in 6ul 20% Dextransulfate in 2X SSC and stored at -20°C until use. 
2.5.2 FISH 
Metaphase chromosomes spread on glass slides were denatured by 70% formamide 
(pH7.7) for 90sec at temp 60°C to 80°C depending on chromosome morphology. The 
slide was then dehydrated by ice-cold 70%, 80% and 100% ethanol series for 2min each 
and was air dried at room temperature. 
Labeled probes were denatured at 95°C for 5miii, then immediately chilled on ice for 
5min and pre-warmed to 37°C for 30min. Two labeled probes were mixed together prior 
to hybridization. Labeled probes were then applied onto denatured metaphase 
chromosomes and incubated at 37°C overnight in a dark humid chamber. 
Post-hybridization washes were carried out in 50% formamide, 2x SSC at 37°C for 4min 
and finally 4x SSC at room temperature at Imin. Chromosomes were counterstained in 
DAPI, hybridization signals were evaluated under a fluorescence microscope (Leitz). 
Images of interphase and metaphase were captured through a cooled CCD camera by the 
Cytovision version 3.1 (Applied Imaging Ltd.). 
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2.6 5-AZA-2'-DEOXYCYTIDINE & TRICHOSTATIN A TREATMENT 
ON CELL LINES 
In 100mm petri-dish, cells at 80% confluent were exposed to 
5-Aza-2'-deoxycytidine (5-Aza) or Trichostatin A (TSA) or the combination of both. For 
5-Aza treatment, \\xM 5-Aza was added to the culture and fresh medium with 5-Aza was 
changed every 24hr for up to 72hr. For TSA treatment, cells were exposed to 300nM 
TSA in medium for 24hr. In combination treatment, medium with l|iM 5-Aza was 
changed every 24hr for up to 72hr followed by 300nM TSA for an additional 24hr. A 
parallel-untreated cell culture was included with all experiments as control. 
2.7 BISULFITE MODIFICATION OF DNA 
Bisulfite modification of DNA was done using EZ DNA Methylation Kit (Zymo 
Research), which converts all unmethylated cytosines to uracils by deamination and 
leaving methylcytosines unaltered. One microgram of DNA in 45ul dilution buffer was 
added and allowed to incubate with DNA at 37°C for 15min. One hundred microliter CT 
Conversion Reagent was subsequently added to each sample, vortexed gently and 
incubated at 50°C for 16hr in the dark. The sample was then incubated on ice for lOmin 
before transferring to a Zymo-Spin I Column and centrifuged at 13,200 rpm for 30sec. 
DNA attached on the membrane of the Zymo-SpinColumn was washed and 
desulphonated by adding 200ul of washing buffer and desulphonation buffer followed 
by centrifugation. Finally, 30ul elution buffer was added to the membrane to elute the 
bisulfite modified DNA. 
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2.8 METHYLATION-SPECIFIC PCR (MSP) 
In 25ul PCR reaction mix, 5ul bisulfite modified DNA was added to 2.5ul lOX 
PCR Buffer, 2ul 25mM MgCb, 3.125ul 2mM dNTP，0.2ul 5U/ul AmpliTaq Gold and 
0.5ul each of the sense and anti-sense primers. Different sets of primer pairs that 
targeted methylated or unmethylated sequences of ATF5 were designed by MethPrimer 
(http://www.ucsf.edu/urogene/methprimer/). The thermal cycling conditions used were: 
12min at 95°C, followed by 40 amplification cycles of denaturing at 95°C for 45sec, 
30sec of primer specific annealing temperature and extension at 72°C for Imin with a 
final extension of 1 Omin at 72°C. 
In MSP experiments, CpGenomeTM Universal methylated DNA was used as 
positive control for methylated sequences, human normal liver DNA served as positive 
control for unmethylated sequences and water as negative control. 
After PCR amplification, 20ul of the PCR products were analyzed on 10% 
polyacrylamide gel electrophoresis. 
2.9 BISULFITE DNA SEQUENCING 
The PCR assay was done as described in the previous section. The PCR products 
obtained were analyzed by agarose gel electrophoresis. On confirming the absence of 
non-specific PCR products, 4ul of PCR product generated was cloned into 
pCR®2.1-T0P0® vector and later transformed into TOP 10 Escherichia coli {E.coli) 
using the TOPO TA Cloning® Kit. After transformation, 30ul of TOP 10 E.coli was 
plated on LB plate containing O.lmg/ml Ampicillin and incubated at 37°C for 16hr. 
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Twelve colonies were picked for PGR confirmation of specific sequence. Ten 
colonies of the 12 colonies were selected for further culture expansion. Colonies were 
inoculated in LB broth with O.lmg/ml Ampicillin at 37°C for 16hr in a shaking 
incubator at 220rpm. Plasmid D N A was extracted by QIAprep® Spin Miniprep. Two 
microliter plasmid D N A was subjected to sequencing reaction according to the method 
described in section 2.4.2 using the Ml3 primer. 
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2.10 QUANTITATIVE R E V E R S E TRANSCRIPTION P G R (QRT-PCR) 
Total R N A was extracted from cell lines as described in section 2.3. Four 
microgram of R N A in 20ul volume was subjected to DNase reaction by adding 2.5ul of 
RQl DNase in lOX Reaction Buffer and 2.5ul of lU/ul RQl RNase-Free DNase in order 
to remove any contaminating D N A . To ensure absence of contaminating D N A , P G R 
without reverse transcription was performed. One microliter DNase-treated total R N A 
was subjected to PGR reaction using the primers targeting genomic beta-globin gene 
(sense: 5'-GAA G A G C C A A G G A C A G G T AC-3' and antisense: 5'-CAA CTT C A T 
C C A C G T T C A CC-3’）with annealing temperature of 60°C. The PGR product obtained 
was analyzed by agarose gel electrophoresis. On confirming the absence of 
contaminating D N A , further qRT-PCR analysis was carried out. 
First strand c D N A was constructed from total R N A . Twenty-four microliter 
DNase-treated total R N A was subjected to reverse transcription reaction using TaqMan® 
Reverse Transcription Reagents. The reaction mixture contained 6.23ul of lOX R T 
Buffer, 13.71ul of 2 5 m M MgCb, 12.47ul of lOmM dNTP mix, 3.12ul ofSOuM Random 
Hexamers, 1.25ul of 20U/ul RNase Inhibitor and 1.56ul of 50U/ul MultiScribe™ 
Reverse Transcriptase. The reaction was performed as follows: lOmin at 25°C, 30min at 
48°C and 5min at 95°C. 
QRT-PCR experiments were done by S Y B R Green PGR Core Reagents for ATF5 
and p-actin quantification described in chapter 3. Since a more specific Taqman probes 
for ATF5 was made available at the time of initiating the investigations described in 
chapter 4，Taqman probes for ATF5 (Hs00247172—ml) with 18s (Hs99999901_sl) as 
internal control were employed. 
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In SYBR Green PCR analysis, 2ul reverse transcription product was added to 23ul 
PCR reaction mix containing 2.5ul lOX SYBR® Green PCR Buffer, 2ul 2 5 m M MgCb, 
0.25ul lOmM dNTP, 0.25ul 5U/ul AmpliTaq Gold and 0.5ul lOuM for each of the sense 
and anti-sense primers. The reaction was performd in 96-well optical tray and the 
thermal cycling conditions were as follows: 95°C for 1 Omin, followed by 50 cycles of 
95°C for 15sec and 60°C for Imin. The specificity of primers was assessed by the 
melting curve generated at the end of cycle reaction. Figure 2.3 shows the graphic 
presentation of the QRT-PCR results obtained in H C C cell lines. The primer used for 
A TF5 and internal control P-Actin are listed in Table 2.1. 
In Taqman PCR Core assays, 2ul reverse transcription product were added to 18ul 
PCR reaction mix containing lOul Taqman® Universal PCR Master Mix and lul 
Taqman Probe. The reaction was also performed in 96-well optical tray and the thermal 
cycling conditions were as follows: 50°C for 2min, 95°C for 1 Omin, followed by 50 
cycles of 95°C for 15sec and 60°C for Imin. The emission intensity was detected by the 
iCycler detection system using fluorophore FAM490. Threshold cycles were averaged 
from triplicate reactions and the expression in cell lines was determined relative to the 
mean value derived from 3 normal liver tissues was determined. To adjust for variations 
in starting template, the gene expression in cell lines, primary tumors and adjacent 
non-malignant liver tissues was normalized with the internal reference gene (18s). 
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Table 2-1. Primers for QRT-PCR 
G e n e P r i m e r s A n n e a l i n g T e m p . 
ATF5 Sense 5'-GAG T G G C G A C A G GAT A G A GC-3' 60。C 
Anti-sense 5'-CCT C C C T C C CTT A G C GTA G T G T-3’ 
(3-Actin Sense 5'-CGC G A G A A G ATG A C C C A G AT-3， 60。C 
Anti-sense 5'-GTA C G G C C A G A G G C G TAG AG-3' 
A. 
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Figure 2.3 Graphical presentation of results obtained from quantitative RT-PCR A) 
Amplification curves of (1) ATF5 and (2) loading control P-actin and B) dissociation 
curves generated on ATF5 and p-actin suggested specific PGR amplification 
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2.11 IN-VITRO A N D IN-VIVO F U N C T I O N A L E X A M I N A T I O N 
2.11.1 ATF5 Transfection 
Two cell lines (Hep3B and HKCI-Cl) were used in the functional study of ATF5 in 
this thesis. Hep3B was obtained from the American Type Culture Collection (ATCC, 
Rockville, M D ) and was cultured in D M E M Medium containing 10% fetal bovine serum, 
lOOuM M E M Non-Essential Amino Acids Solution and Penicillin-Streptomycin. 
HKCI-Cl, on the other hand, is a H C C cell line that was established from our laboratory 
(Chan et al. 2005) and was cultured in AIM-V® Medium containing 10% fetal bovine 
serum, 2 m M L-Glutamine and Penicillin-Streptomycin. Both cultures were kept in a 
humidified incubator at 37°C in an atmosphere of 5% CO2. 
In constructing the ATF5 expression vector, an I M A G E clone ( M G C 849), which 
encodes the full length human ATF5 cDNA, was sub-cloned into the pcDNA3.1 vector 
through the Xho\ and EcoRl sites. Prior to transfection pcDNA3.1-^rF5, the ATF5 
sequence cloned was first confirmed by sequencing. After sequence confirmation, 
pcDNA3.1-^rF5 was transformed into E.coli D H 5 a and expanded in the plasmids D N A 
was extracted using QIAGEN® Plasmid Midi Kit. 
Cells were seeded at a density of 5x10^ cells onto a 100mm dish and cultured in 
15ml medium without antibiotics for 48hr. After 48hr, the cells were transfected with 
either pcDNA3.1 vector or pcDNA3.1-v4rF5 in Lipofectamine 2000. Empty vector 
pcDNA3.1 served as a negative control in transfection experiments. Twenty-four 
microgram of plasmid D N A and 60ul Lipofectamine 2000 were incubated with 
O P T I - M E M ® I separately in a total volume of 1.5ml each at room temperature for 5min. 
O P T I - M E M ® containing plasmid D N A and Lipofectamine 2000 were then mixed to 
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achieve a final volume of 3ml and were allowed to incubate at room temperature for a 
further 20min. The mixture was then added to the cells. After 6hrs of incubation, the 
medium was replaced by complete medium and cells were allowed to grow for an 
additional 20hr. 
In order to select stably transfected cells, medium containing IX Geneticin was 
used to culture the cells at the third day. After Geneticin selection for a month or so, 
single colony of cells were cultured separately. 
2.11.2 Cell Growth Assay 
Transfected cells were seeded onto a 96-well culture plate at a density of 2x10^ cells 
per well at day 0. Five replicate wells that represented each time point was prepared. At 
24hr time intervals for 7 consecutive days, cell growth was measured by 3-(4, 
5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) Assay. Medium was 
first removed and 50ul of 1 .Omg/ml M T T was added to the cells. Cells were incubated 
with M T T at 37。C for 4hr. M T T was then removed and lOOul D M S O was added to the 
cells to dissolve the purple formazan crystals. Cell viability was determined by the 
amount of purple formazan crystals formed and measured by spectrophotometric means 
at absorbance 570nm (SPECTRA Rainbow v2.02 plate reader). Measurements 
determined from 5 replicates in 2 independent experiments were expressed as a 
percentage of maximum absorbance. 
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2.11.3 Xenograft Development 
The Balb/C nude mice used in this study were obtained from the animal care unit of 
the Chinese University of Hong Kong. All the mice used were male aged 6-8 weeks at 
the beginning of the study. They were provided with a diet of standard mouse chow and 
water ad libitum. Stably transfected Hep3B cells were trypsinized and resuspended in 
D M E M medium. About 1x10^ cells were injected subcutaneously into the back of mice 
and allowed to grow. The weight and size of the mouse were monitored every 2 days. 
Size of tumor was estimated by measuring its width, length and depth with an electronic 
caliper. 
2.12 C O D E L I N K EXPRESSION M I C R O A R R A Y 
In an effort to define the downstream pathway(s) and target(s) modulated by ATF5, 
expression microarray analysis was performed on stably and transiently transfected 
Hep3B cells. The CodeLink Expression UniSet Human 20K I Bioarray (Amersham 
Biosciences) was employed. Two hundred femtogram of araB, entF, fixB, gnd, hisB and 
leuB bacterial control m R N A s and T7 oligo(dT) primer were added to 2ug of total R N A 
extracted from Hep3B transfected and untransfected cells. The mixture was then 
incubated at 70°C for lOmin and chilled on ice. First strand c D N A was synthesized by 
addition of IX first-strand buffer, I m M dNTP mix, l.Oul RNase inhibitor and l.Oul 
reverse transcriptase to R N A . The reaction mixture was incubated at 42°C for 2hr. In the 
synthesis of second strand cDNA, IX second-strand buffer, I m M dNTP mix, 2.0ul D N A 
polymerase mix and l.Oul RNase H were then added to the reaction mixture and allowed 
to incubate at 16°C for 2hr. The double-stranded c D N A synthesized was purified by 
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QIAquick PGR Purification Kit and was concentrated to <9.5ul final volume by 
SpeedVac concentrator. 
Concentrated double-stranded c D N A was then subjected to in-vitro transcription to 
synthesize biotin-labeled cRNA. Four microliters each of lOX T7 Reaction Buffer, T7 
ATP, T7 GTP, T7 CTP, lOX T7 enzyme mix, 3.0ul of T7 UTP solution and 7.5ul of 
l O m M biotin-11-UTP were incubated with the double-stranded c D N A for 14 hr at 37°C. 
The c R N A synthesized was purified by RNeasy Mini Kit (Qiagen, Germany) according 
to the manufacturer's protocol. The cRNA concentration and quality were determined by 
the ratio of absorbance at 260nm and 280nm, and M O P S gel electrophoresis in which 
the optimal product size should be about 1200bp. 
The biotin-labeled cRNA was fragmented by addition of 5ul of 5x fragmentation 
buffer at a ratio of 5ul to lOug c R N A in a total volume of 20ul. Following incubation at 
94°C for 20min, the reaction mixture was cooled on ice immediately for at least 5min. 
Then, 208ul hybridization buffer was added to 52ul of fragmented c R N A and allowed to 
incubate at 90°C for 5min to denature the cRNA. This was followed by cooling in ice for 
at least 5min and no more than 30min. Two hundred and fifty microliter of denatured 
c R N A in hybridization buffer was loaded onto the 20K bioarray and the hybridization 
took place in a shaking incubator at 300rpm for 18-24hr at 37°C. 
In post-hybridization washes, the bioarray was washed in 0.75x T N T buffer 
pre-warmed at 46°C to remove non-specific and unbound sequences. Later, the bioarray 
was incubated with 3.4ml of 1.7ug/ul CyS-steptavidin/TNB at ambient temperature for 
30min. This was followed by washing in Ix T N T for 4 times for 5min each. Finally, the 
bioarray was washed with O.lx SSC/0.05% Tween 20 for 30sec and spun dried by 
centrifugation. The array was scanned for signals with the GenePix 4000B scanner and 
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analyzed by CodeLink Expression Analysis software v.4. The differential gene 
expression was considered, when the expression fold change was greater than 2-fold or 
less than 0.5-fold. 
2.13 Statistical Analysis 
The differences between relative growth of cells transfected with vector alone and 
vector containing ATF5 clone were compared by paired Student's t test. The correlation 
between ATF5 and Id-1 was examined by Pearson's Correlation. Statistical analysis was 
performed by Graphpad Prism 3.0. A difference or correlation was considered 
significant when a p-value of less than 0.05 was achieved. 
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Chapter 3 




Previous transcriptional mapping study on Chr.l9q from our group has led to the 
novel identification of common ATF5 down-regulations in H C C and a tumor 
suppressive role of ATF5 in H C C was further suggested in the functional studies 
described in the following chapter 4. In this chapter, the potential inactivation 
mechanisms that underlie the repression of ATF5 were investigated in a large panel of 
H C C cell lines that included early-passages of H C C cultures and established cell lines. 
These cell lines displayed a common down-regulation of ATF5 and represent a 
homogenous source of malignant hepatocytes in the elucidation for inactivating 
mechanism. 
Genomic mutation is one of the common mechanisms involved in gene inactivation. 
Mutations have been suggested in various tumor suppressor genes and subsequent 
functional implications in carcinogenesis. For example, p53 mutations are common in 
human malignancies including breast cancer, colorectum cancer and ovary cancer, where 
mutations occur mainly within exon 5 to exon 8 (lARC TP53 database). In this chapter, 
mutation of ATF5 genomic D N A in 18 H C C cell lines was examined by direct D N A 
sequencing. The ATF5 sequence of H C C cell lines were compared to the sequences 
derived from 10 normal liver samples and 3 lymphocytic D N A from healthy individuals. 
Another frequent mechanism in the inactivation of tumor suppressor genes is copy 
number loss. It has been suggested that tumor suppressor BRCAl, that is involved in the 
transcriptional regulation and D N A repairing (Welcsh et al. 2001), is frequently 
down-regulated by copy number loss. A causative role of copy loss besides mutation was 
further implicated in association with the development of breast cancer, ovarian cancer 
and adenocarcinoma (Magdinier et al. 1998; Beger et al. 2004; Kato et al. 2004). In an 
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attempt to examine if copy loss played a role in the down-regulation of ATF5, copy 
number enumeration by FISH analysis was performed on the same 18 H C C cell lines as 
described above. 
Promoter hypermethylation is a more recently discovered causative mechanism in 
the inactivation of tumor suppressor genes. In bladder cancer, promoter 
hypermethylation of the tumor suppressor pi6 gene was found to be the major 
mechanism underlying its down-regulation (Kawamoto et al. 2006). This methylation 
event has also been reported in other malignancies such as gastric cancer, non-small cell 
lung cancer and H C C (An et al. 2002; Zhang et al. 2002; Kanyama et al. 2003). In the 
epigenetic control, histone acetylation is also another important mechanism in the 
regulation of gene expression. Histone acetylation is a reversible process which operates 
through the actions of the histone acetyl transferases (HATs) and histone deacetylases 
(HDACs) enzymes. H A T decreases the affinity of D N A binding to histone and releases 
the chromatin structure for gene expression (Hong et al. 1993; Lee et al. 1993; 
Vettese-Dadey et al. 1996; Hernandez et al. 2006). On the other hand, histone 
deacetylation by H D A C will make the chromatin structure more condense and so 
represses gene transcription. During D N A methylation, D N A methyltransferase will add 
methyl groups to cytosines of CpG sites. These methylated cytosines are recognized and 
bound by methyl-CpG-binding protein, which can recruit H D A C s to the methylated sites 
and convert the chromatin into a closed structure. As a result, genes containing a 
hypermethylated promoter region can cause transcriptional silencing (Worm et al. 2002). 
In order to investigate whether ATF5 down-regulation was associated with 
promoter hypermethylation and/or histone deacetylation, the expression of ATF5 in 6 
H C C cell lines were first examined by 5-Aza-2‘-deoxycytidine (5-Aza) and Trichostatin 
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A (TSA) treatments. The 5-Aza is a cytidine derivative and a demethylating agent, while 
T S A is an H D A C inhibitor. Subsequent to the in-vitro analysis by 5-Aza and TSA, 
further investigation on the promoter methylation status were carried out on ATF5, 
which contains 2 CpG islands within its promoter region (Figure 3.2). Methylation 
specific P G R and bisulfite sequencing were performed on the 18 H C C cell lines. As CpG 
island 2 is closest to the 5'UTR of ATF5, methylation status of this CpG island was first 
examined by MSP. Furthermore, bisulfite sequencing was carried out to confirm the 
results of M S P and to examine the methylation status of CpG island 1. 
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3.2 Materials and Methods 
3.2.1 Cell Lines 
Eighteen H C C cell lines were subjected to direct D N A sequencing. These included 
11 in-house established cell lines HKCI-1-4, 7-10, C1-C3, and 7 cell lines SNU387, 
SNU398, SNU475, PLC5, Huh7, Hep3B and HepG2 acquired from the American Type 
Culture Collection (ATCC，Rockville, M D , USA). All HKCI-series of cell lines and 
A T C C acquired cell lines were cultured according to procedure described in Section 
2.11.1. In addition to D N A sequencing, promoter methylation analysis and copy number 
examination by FISH were also performed on these 18 cell lines. 
3.2.2 Mutational Analysis 
The reference sequence of ATF5 from the U C S C database was used to design P C R 
primers and later sequence alignment (Figure 3.1). ATF5 contains one 5'Untranslated 
Region (5'UTR) and 2 exons. Since exon 2 (1.47 kb) is too large to allow efficient direct 
sequencing, this region was sub-divided into 2 product sizes of 644 kb and 861kb in 
sequencing analysis. The sequencing primers for the 4 regions and the annealing 
temperatures used have been listed in Table 3-1. 
P C R amplification of the 4 regions was done by the AmpliTaq Gold D N A 
polymerase. However, specific band of Exon 2-1 has failed to be obtained in repeated 
attempts using the AmpliTaq Gold D N A polymerase. Modification on the PCR condition 
for Exon 2-1 was hence carried out, and PCR specificity was achieved by the FastStart 
High Fidelity PCR system. 
After PCR amplification, the products were purified according to the method 
described in section 2.4.1 and cycle sequencing was performed according to Section 
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2.4.2. Final sequences obtained were aligned using online software "Multiple sequence 
alignment with hierarchical clustering" (http://prodes.toulouse.inra.fr/multalin/). All 
sequences were aligned with reference sequence form U C S C database and the sequence 
of 18 H C C cell lines were compared to sequences obtained from 10 normal livers and 
lymphocytic D N A from 3 healthy individuals. 
3.2.3 Copy Number Loss 
Copy numbers of ATF5 in 18 H C C cell lines were examined by dual-labeled FISH 
according to the method described in Section 2.5. An internal reference probe on 
Chr. 1 p31 (BAC clone RP11-110A23) was used as a control for ploidy status. This region 
was employed since it did not display any imbalances in all 18 cell lines studied as 
determined from previous Comparative Genomic Hybridization (CGH) study. In the 
present study, the B A C clone RP11-510I16 which contained the ATF5 gene was directly 
labeled with spectrum green, while the reference probe RP11-110A23 was labeled with 
spectrum orange. 
3.2.4 Epigenetic Control 
In the investigation of epigenetic control in the inactivation of ATF5, the expression 
of ATF5 was first examined by 5-Aza and TSA treatments in 6 H C C cell lines 
(HKCI-Cl, 2，8, 9，10 and Hep3B). The in-vitro procedure was carried out according to 
the procedures described in Section 2.6, and the expression of ATF5 was assessed by 
qRT-PCR using S Y B R Green PGR Core Reagents Kit. 
The methylation status of CpG island 2, which was closest to transcription start site 
of ATF5, was examined by M S P (detailed methodology described in Section 2.8). A total 
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of 18 H C C cell lines, 10 normal liver samples and 3 lymphocytic D N A from healthy 
individuals was investigated. Furthermore, bisulfite sequencing on 4 cell lines was 
carried out to confirm the results of M S P and on 18 cell lines to further analyze the 
methylation status of CpG island 1. Bisulfite sequencing was carried out according to 
the method in Section 2.9 and the results obtained from cell lines were compared to 
three reference normal liver samples. The primers used in M S P and bisulfite sequencing 
are listed in Table 3-2 and Table 3-3 respectively. 
Prior to M S P or bisulfite sequencing, all D N A samples used were first bisulfite 
( 
modified to convert all the unmethylated Cytosine into Uracil (detailed methodology 
described in Section 2.7). (Figure 3.3). 
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I tgtcctcggatcacagtctcttctcactacagtgtcgccgcctctgcctgcgtagccccg | 
I pccarggctctgtagcctcgacccctttgtgcccccggcccgtctccgcgctcaccacgc I 
r7tgcgctctccgctcccaccttctttcttcagccgaggccgccgccgcctctccttgctg I 
I rp)pccatggagjctt.ccactt.tcgcct.tggtgcctgtctrcgcccacntpapr,atcctcc "1 
I pa per, t c g t gcca ^ c t ^ c t gg t gca gcc t c t cc t g 11 pcca t ca g t qcccafycac.c. tpf I 
I gctafaQr;catgtcaftgctggcgaccctggggctggagctggacagggccgtgctccca I 
M S T, A T T. G T F. T, D R A T, T. P 
I ggtagtgggctgggatggctcgtagactatgggaaactccccccggcccctgcccccctg 1 
A S G L G W L V D Y G K L P P A P A P L 
[7f^t�rntatMggtccttgggggagccctggagggcgMr'ttccagtsrggWP?^P?^Pc:(:c I 
A P Y E V L G G A L E G G L P V G G E P 
rctggcaggftgatggcttctctgactggatgactgagcgagttgatttcacagctctcctc I 
L A G D G F S D W M T E R V D F T A L L 
I cctctggaecctcccttaccccccggcaccctcccccaaccttccccaaccccacctgac I 
P L E P P L P P G T L P Q P S P T P P D 
[ctggaagctatggcctccctcctcaagaaggagctggaacagatggaagacttcttccta | 
L E A M A S L L K K E L E Q M E D F F L 
[gatgccccgcccctcccaccaccctccccgccgccactaccaccaccaccactaccacca I 
D A P P L P P P S P P P L P P P P L P P 
I gccccctccctccccctgtccctcccctcct ttgacctcccccagccccctgtcttggat ] 
A P S L P L S L P S F D L P Q P P V L D 
[^ctctggacttgctggccatctactgccgcaacgaggccgggcaggaggaagtggggatg I 
T L D L L A I Y C R N E A G Q E E V G M 
[ccgcctctgcccccgccacagcagccccctcctccttctccacctcaaccttctcgcctg I 
P P L P P P Q Q P P P P S P P Q P S R L 
("gccccctacccacatcctgccaccacccgaggggaccgcaagcaaaagaagagagaccag 
A P Y P H P A T T R G D R K Q K K R D Q 
I aacaagtcggcggctctgaggtaccgccagcggaagcgggcagagggtgaggccctggag "I 
N K S A A L R Y R Q R K R A E G E A L E 
Figure 3.1 Genomic sequence of ATF5 (Accession number NM—012068) from the UCSC database 
Red box: 5，Untranslated Region Blue box: Exon 1 
Green box: Exon 2-1 Yellow highlights the start codon 
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rSgcgagtgccaggggctggaggcacggaatcgcgagctgaaggaacgggcagagtccgtg 1 
G E C Q G L E A R N R E L K E R A E S V 
E R E I Q Y V K D L L I E V Y K A R S Q 
I aggacccgtagctgclt^aagggcaggggtgtggcttctgggggctggtcttcagctcte I 
R T R S C -




ITTpnf t?^tcacctct.ctt.gcgtat.t.tctgg?)tctccttccctcctttctcgtcca?i?itca I 
rToaaafot f t gar r 113 p t r^ f p t r t a t arrrg t r ar a t a ara arraagar a rr gaggr ZZj 
I tgaatttraaarrtgatttrt 
rT7napptggttgtctggggtgggtggagtggcgacaggatagagct.gaaggactatgcaa I 
Faggctaggtgacct tgggacactacectaagggagggaggctaaaggcggccaggt ttgc I 
lagtpr-pggaagatgagcaseccagtgggaggaggggcagggcagggctgtagttggteac ] 
rr^ptPttcattttagctctaagaaaaaaaatcagtgtttcgtgaaggtgttggaPRPPP I 
Fgn t Pt pt c t ？^pt gaggga t ？^cgggpt ac t ga 1111 
Figure 3.1 cont'd 
Green box: Exon 2-1 Pink box: Exon 2-2 
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Figure 3.2 Two CpG islands are located in the promoter region of ATF5 (upstream 
llOObpfromS'UTR) 

















































































































































































































































































































































































































































































ggg i^i g ^ ^ g 
sodium bisutfite 
modification ，『 
ggg gug gau ugu g 
Methylated DNA 
ggg g c ^ gac d^gc"^ g 
sodium bfeulfite 
modification ，f 
ggg g c ^ gau g 
B. 
V^t Sulph oration 







义 Desulphonation 9 
0 义 、 O H 〖A^,丄SI入 
Uraci l Uraci l 
sulphonate 
Figure 3.3 The unmethylated but not methylated Cytosine of CpG can be converted 
to Uracil through bisulfite modification as shown in (B). 
(Figure adapted from Chemicon International) 
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3.3 Results 
3.3.1 Sequencing Analysis of ATF5 Gene 
The genomic sequence of ATF5 in 18 H C C cell lines, 10 normal livers and 
lymphocytic D N A from 3 healthy individuals were aligned with the reference sequence 
from U C S C database. Representative results are shown in Figure 3.4.1. 
Sequencing analysis suggested the absence of ATF5 genomic mutations in all cell 
lines examined except for a few polymorphisms according to NCBI database. 
Nevertheless, a single nucleotide mutation located in Exonl of Hep3B (Figure 3.4.1b) 
was found. However, on further analysis, this base change was a silent mutation that did 
not result in a change in amino acid (CTC^®" -> CTT^'")(Figure 3.4.2). 
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P L C S CCTGTCCTCGGflTCRCIlGTCTCTTCTCflCTflCflGTGTCIlCCGCCTCTGCCTGCGTflGCCCCGGCCflTGGCTCTGTflGCCTCGflCCCCTTTGTGCCCCCGGCCCGTCTCC s 
Huh7 (X丨GTOKGGflKfl[肌[丨[na[flC丨腳而[[[[GG[[肌G[mGfflG[[KGfl[[(XnMG[[[[[GG[a:GKI(;(;G(;G(;Kfl[[fl[G(;(:ra:G(:K i 
HepG2 CCTGTCCTCGGflTCflCeGTCTCTTCTCflCTflCflGTGTCGCCGCCTCTGCCTGCGTRGCCCCGGCCflTGGCTCTGTaGCCTCGRCCCCTTTGTGCCCCCGGCCCGTCTCCGCGCTCflCCflC 
H e p 3 B CCTGTCCTCGGflTCflCflGTCTCTTCTCflCTflCflGTGTCGCCGCCTCTGCCTGCGTflGCCCCGGCCfiTGGCTCTGTflGCCTCGflCCCCTTTGTGCCCCCGGCCCGTCTCCGCGCT^ ', 
S N U 3 8 9 CCTGTCCTCGGHTCflCflGTCTCTTCTCflCTflCflGTGTCGIXGCCTCTGCCTGCGTflGCCCCGGCCflTGGCTCTGTflGCCTCGflCCCCTTTGTGCCCCCGGCCCGTCTCCGCGCTCflCCflCGCC J 
S N U 3 9 8 CCTGTCCTCGGflTCOGTCTCTTCTCflCTflCflGTGTCGCCGCCTCTGCCTGCGTflGCCCCGGCCflTGGCTCTGTRGCCTCGflCCCCTTTGTGCCCCCGGCCCGTCTCCGCGCK 
S N U 4 7 5 CCTGTCCTCGGflTCflCflGTCTCTTCTCflCTflCflGTGTCGCCGCCTCTGCCTGCGTflGCCCCGGCCflTGGCTCTGTflGCCTCGflCCCCTTTGTGCCCCCGGCCCGTCTCCGCGCTCflCCfl^ ‘ 
H K C I - 1 CCTGTCCTCGGHTCflCftGTCTCTTCTCflCTflCflGTGTCGIXGCCTCTGCCTGCGTfiGCCCCGGCCflTGGCTCTGTflGCCTCGflCCCCTTTGTGCCCCCGGCCCGTCTCCGCGCK ' |j 
HKCI-C1 CCTGTCCTCGGflTCfl(liTCTCTTCTCf)CTflCflGTGTCG(XGCCTCTGCCTGCGTflGCCCCGGCCflTGGCTCTGTflGCCTCGflCCCCTTTGTGCCCCCGGCCCGTCTCCGC “ 
H K C I - 2 CCTGTCCTCGGHTCflCflGTCTCTTCTCflCTflCflGTGTCGCCGCCTCTGCCTGCGTflGCCCCGGCCflTGGCTCTGTRGCCTCGflCCCCTTTGTGCCCCCGGCCCGTCTCCGCGCTCfl^ ‘ 
H K C I - 3 CCTGTCCTCGGflTCflCftGTCTCTTCTCftCTflCflGTGTCGCCGCCTCTGCCTGCGTflGCCCCGGCCflTGGCTCTGTflGCCTCGflCCCCTTTGTGCCCCCGGCCCGTCTCCGCGCTCflCCflCGCCTGCG J 
H K C I - 4 CCTGTCCTCGGIITCflCflGTCTCTTCTCflCTflCflGTGTCGCCGCCTCTGCCTGCGTflGCCCCGGCCflTGGCTCTGTaGCCTCGRCCCCTTTGTGCCCCCGGCCCGTCTCCGCGCTCflCCflCGCCTGCGCTC 
H K C I - C 2 CCTGTCCTCGGflTCRCIlGTCTCTTCTCflCTflCflGTGTCGCCGCCTCTGCCTGCGTRGCCCCGGCCflTGGCTCTGTflGCCTCGflCCCCTTTGTGCCCCCGGCCCGTCTCCGCGCTCflCCflCGCCTGC ！ 
H K C I - C 3 CCTGTCCTCGGfiTCflCflGTCTCTTCTCflCTflCfiGTGTCGCCGCCTCTGCCTGCGTflGCCCCGGCCflTGGCTCTGTflGCCTCGRCCCCTTTGTGCCCCCGGCCCGTCTCCGCGCK ‘ 
H K C I - 7 CCTGTCCTCGGflTCflCflGTCTCTTCTCflCTflCflGTGTCGCCGCCTCTGCCTGCGTflGCCCCGGCCflTGGCTCTGTflGCCTCGflCCCCTTTGTGCCCCCGGCCCGTCTCCGCGCTCflCCflCGCC 丨 
H K C I - 8 CCTGTCCTCGGflTCflCflGTCTCTTCTCflCTflCflGTGTCGCCGCCTCTGCCTGCGTflGCCCCGGCCflTGGCTCTGTflGCCTCGflCCCCTTTGTGCCCCCGGCCCGTCTCCGCGCTCfiCCflCGCCTGCGCTC 
HKCI-9 [丨G[[IG[GIflG[[[[GG[[flIGG[mGIflG[[KGfl[a[mGM[[[[GG[raK丨[[GlEKIEflGGIXMG[丨(： “‘ 
HKCI-10 [[IGKaCGGflKflC卩GKKn[ranfl[flGTGICG[CG[[丨[服CIGCG而[[[[GG[⑶TGG[丨[mflG[[丨[Gfl[[(:mTG孤[[[CGG(X[GKK[G[G[Kfl[(:fl(;GCaGCGCTC 
Figure 3.4.1a Alignment of ATF5 5'UTR region with the reference sequence from U C S C 
database 
Lym: Lymphocytic D N A 
LN: Normal liver samples 
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131 140 150 160 170 180 190 200 210 220 230 240 250 260 
I + — • • 一 - + + + — — — - + + + + 和 — I 
U C S C GGCGflCCCIGGGGCTGGflGCTGGRCfiGGGCCCTGCTCCCflGCTflGTGGGCTGGGflTGGCICGTflGflCTflTGGGflftflCTCCCCCCGGCCCCTGCCCCCCTGGCTCCCTflTGflGGTCCTTGGGGGflGCCCTG 
Lym1 GGCGflCCCTGGGGCTGGflGCTGGflCflGGGCCCTGCTCCCflGCTflGTGGGCIGGGaiGGCTCGTflGflCIRTGGGflflflCTCCCCCCGGCCCCTGCCCCCCTGGCTCCCTfiTGflGGTCCTTGGGGG 
Lym2 GfiCGflKCTGGGGCTGGflGCTGGflCflGGGCCCTGCTCCCIlGCTflGTGGGCTGGGfiTGGCTCGTflGBCTflTGGGflflflCTCCCCCCGGCCCCTGCCCCCCTGGCK 
L y m 3 GGCGflCCCTGGGGCTGGIiGCTGGflCflGGGCCCTGCTCCCfiGCTflGIGGGCTGGGflTGGCTCGTflGflCIflTGGGRflflCTCCCCCCGGCCCCTGCCCCCCTGGCTCCCTflTGflGGTCCnGGGGGfl 
LN1 GG[Gft[[[raGGaGGflG[IGGflMGGG[C[IG[K(XflG(;iflGniGG[丨 GGGfPG[丨[GTOfOfilGGGfllEKIXIXIllXIXIGIXIXIXIGGIiraGmGflGGranGGGGGflGCCCTG 
LN2 GGCGflCCCTGGGGCTGGflGCTGGIlCfiGGGIXCTGCTCCCIlGCTIlGTGGGCTGGGflTGGCTCGTRGIlCTflTGGGflRflCTCCCKCGGCCCCTGCCra 
L N 3 GGCGflCCCTGGIETGIiflGCTGGflCflGGCCCCTGCTCCCflGCTftGTGGGCTGGGRTGGCTCGTflGflCTflTGGGRflflCTCCCCCCGGCC 
L N 4 GGCGflCCCTGGGGCTGGflGCTGGflCflGGGIXCTGCTCCCftGCTflGTGGGCTGGGflTGGCTCGTflGflCTflTGGGflRflCTCCCCCCGGCCCCTGCCCCCC^ 
LN5 GGCGflOXTGG腳IG_nGG_GGG�CnG[ra(:flG(:iflGniGG(:iGGGflIGG(:iGIflGfl(：丽GGGflfifiaiXIXIGGIXIXIGKIXIiaGGGKIXmGflGGKmGGGGGflGIXaG -
LN6 GGCGflCCCTGGGGCTGGHGCTGGflCflGGGCIXTGCTCCCflGCTflGTGGGCTGGGfiTGGCTCGTflGfiCTflTGGGflflflCTCCCCCCGGCCCCTGCCCCCCTGGCTCCCTflTGflGGTCCTTGG 
L N 7 GGCGflCCCTGGIETGGIlGCTGGflCflGGGCCCTGCTCCCflGCTftGTGGGCTGGGflTGGCTCGTfiGflCTflTGGGflflflCTCCCCCCGGCCCCTGCCCCCCTGGCTCC^ 
LN8 GGCGflCCCTGGGGCTGGflGCTGGflCiGGCKTGCTCCCflGCTflGTGGGCTGGGflTGGCTCGTfiGflCTflTGGGflfieCTCCCCCCGGCCCCTGCCCCCCTGGCTCCCTfl 
L N 9 GGCGflCCCTGGGGCTGGflGCTGGflCflGGGCCCTGCTCCCflGCTflGTGGGCTGGGHTGGCTCGTflGflCTRTGGGflflflCTCCCCCCGGCCCCTGCCCCCCTGGCTCCCTflTGflGGTCCTT^ 
LN10 咖GflCCCIGGGGC丨GGflKIMfl[fiGGGCCC丨GCraCflG[丨flGIGGGC丨GGGftlGGCraraft[丽GGGflflflmraC[GGCraM[[C(:aGGCra(；而GIlGGKmGGGGGflGCCCTG 
PLCS 丨GGflKra_GMraiG[ra[flG[IflGIGGGaGGGflIGG(:i(:G_fl(：丽GGGflGKGGGIXGGI：!：!：[丨GKIXIXIGGI：丨[[I：而GIGG丨(XnGGGGGflGCCCTG 
H u h 7 GGCGflCCCTGGGGCTGGfiGCTGGflCRGGGCCCTGCTCCCflGCTflGTGGGCTGGGflTGGCTCGTflGflCTRTGGGflflflCTCCCCCCGGCCCCTGCCCCCCTGGCTCCCTflTG -
HepG2 GGCGflCCCTGGGGCTGGflGCTGGflCflGGGCCCTGCTCCCflGCTflGTGGGCTGGGflTGGCTCGTfiGflCTflTGGGfiflflCTCCCCCCGGCCCCTGCCCCCCTGGCTCCCTflTGftGGTCCTT^ , 
H e p 3 B GGCGflCCCTGGGGCTGGflGCTGGRCflGGGCCCTGCTCCCflGCTflGTGGGCTGGGBTGGCTCGTflGflCTeTGGGRflflCTIICCCCCGGCCCCTGCCCCCCTGGCTKCTfl 
S N U 3 8 9 咖GflCCCTMGKTGfflGCTGGflCflGGGC(XTGCKC[flGCTflGTGGGCTGGGflTGGCTCG僅lOflTGGGfl赃TCCCCCCGGCCCCTGIXCCCCTGGCTttCTflTGflGGTCCnGGGGGflGCCCTG 
SNU398 GGCGfllXCTGGIETGGflGCTGGflCflGGGCCCTGCICCCflGCTflGTGGGCTGGGflTGGCTCGTflGflCTflTGGGflflftCTCCCCCCGGCCCCTGCCCCCCTGGCTCCCTfl “ 
SNU475 GGCGflCCCTGGGGCTGGflGCTGGflCflGGGCCCTGCTCCCflGCTflGTGGGCTGGGflTGGCTCGTfiGflCTflTGGGflflflCTCCCKCGGCCCCTGK 
H K C I - 1 GGCGflCCCTGGGGCTGGflGCTGGflCflGGGCCCTGCTCCCflGCTflGTGGGCTGGGfiTGGCTCGTflGeCTflTGGGflaflCTCCCCCCGGCCCCTGCCCCCCTGGCTCCCTflTGflGGTCC . 
H K C I - C 1 GGCGflCCCTGGGGCTGGflGCTGGftCflGGGCCCTGCTCCCflGCTflGTGGGCTGGGHTGGCTCGTflGflCTflTGGGaflflCTCCCCCCGGCCCCTGCCCCCCTGGCTCCCTflTGflGGTCCTTGGGG ‘  
H K C I - 2 GGCGflCCCTGGGGCTGGflGCTGGftCfiGGGCCCTGCTCCCIlGCTftGTGGGCTGGGflTGGCTCGTflGflCIflTGGGeflflCTCCCCCCGGCCCCTGCCCCCCTGGCTCCCT^ 
H K C I - 3 GGCGflCCCTGGGGCTGGflGCTGGflCflGGGCCCTGCTCCCflGCTflGTGGGCTGGGRTGGCTCGTflGRCTflTGGGflRflCTCCCCCCGGCCCCTGCCCCCCTGGCTCCCTflTGflGGTCCn 
H K C I - 4 GGCGflCCCTGGGGCTGGflGCTGGflCflGGGCCCTGCTCCCflGCTflGTGGGCTGGGflTGGCTCGTftGflCTflTGGGflflflCTCCCCCCGGCCCCTGCCCCCCTGGCTCCCTflTGflGGTCCT^ 
HKCI-C2 MCGflCCCTGG腳TGGflGCTGGflCflGGGCCCTGCTCCCflGCTRGTGGGCTGGGflTGGCTCGTRGflC而GGG圓CTCCCCCCGGCCCCTGCCCCCCTGGCTCCCTflTG冊^  T 
H K C I - C 3 GGCGflCCCTGGGGCTGGflGCTGGflCfiGGGCCCTGCTCCCflGCTftGTGGGCTGGGeTGGCTCGTflGflCTflTGGGieCTCCCCCCGGCCCCTGCCCCCCTGGCTCCCTflTGflGGTCCTTGGG « 
HKCI-7 GGCGflCCCTGGGGCTGGflGCTGGIlCflGGGCCCTGCTCCCflGCTflGTGGGCTGGGflTGGCTCGTfiGflCTflTGGGflflflCTCCCCCCGGCCCCTGCCCCCCTGGCTCCCTflTGflGGK p 
H K C I - 8 GGCGflKCTGGGGCTGGflGCTGGIKflGGGCCCTGCTCCCflGCTftGTGGGCTGGGflTGGCTCGTflGflCTflTGGGflflflCTCCCCCCGGCCCCTGCCCCCCTGGCTCCCT^ 
H K C I - 9 GGCGIlCCCTGGGGCTGGflGCTGGflCflGGGCCCTGCTCCCflGCTRGTGGGCTGGGRTGGCTCGTflGRCTflTGGGflflfiCTCCCCCCGGCCCCTGCCCCCCTGGCTCCCTflTGflGGTCC “ 
H K C M O GGCGflCCCTGGGGCTGGflGCTGGfiCflGGGCCCTGCTCCCflGCTflGTGGGCTGGGflTGGCTCGTflGeCTeiGGGflflflCTCCCCCCGGCCCCTGCCCCCCTGGCTCCCTflTG 
Figure 3.4.1b Alignment of ATF5 Exon 1 region with the reference sequence from U C S C 
database. A silent mutation was found in Hep3B. 
Lym: Lymphocytic D N A 
LN: Normal liver samples 
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1 10 20 30 40 50 GO 70 80 90 100 110 120 130 
I 4 —+ + — + + + • - + + 1 
UCSC GIGfl 丨GG[n[KIGfl[服fl 丨Gfl[丨GflGGGflGnGflnKfl[咖丨[[瓜[nfl[raraG[fl�[[TO[^fl[[m[[[flflra[fi[[丨Gfl[[丨GGfl腳而 GGCCTC 
Lym1 GIGflIGG[n[mGfl[磁fl 丨Gfl[丨G 舰GflGnGflm[OG[丨舰[ra[[僅[[[[[GG[fl[[[K[[[〖flflrcm〔[_ra[fl[[IGfl[[IGGfl 舰 m G G C C T C 
Lym2 G 丨GflIGG[n[KIGfl[Iffifl 棚[IGflKGAGnGflnKfl 咖[丨[[丨[丨 GGflG[[K•丨fl[[[[raG[flrara[Ofl[[n(;(;(;(l(XC(l[IGfllXIGGflflG(：冊GGIXK 










LN10 G r a i G G〔n [ m G f l [丨 G G f l _ [ I哪咖 G n G f l m C f l•[丨僅 [ [ [ [ [ G G [ f l [ [ [ K [ [ [ [ f i f l K n [ [ r a f l [ [咖 [ [ I G虹丨 G G f l f l G [丨肌 G I X K 
PLCS GIGfl 丨GG[na[Iffl[IGGfl丨Gfl[側G[GflGnGflmCfl[flG[I[raK[(:i[IGG 咖[丨[[mflraraGGGflGGCraK^GGmraiEIXCfllX 側(X丨GGflfEMGGCCTC 
Huh7 GraiGGm[丨[卿[IGGfl 丨GflC 側G[GflGnGflmCfl[flG[KKaC[[K 丨 GGflGGCKCCCIIiraGGlllXKCQfllEniXIXflfCaXIE 丨GfllXIGGflfiGCIfllGGCCTC 
HepG2 (i 棚丨 GGma[IGfl[IGGflIGflaGflKGflGnGflm[fl[赃 [丨 GGfiGGmiXnflraraGGIllXKIXIXflfllXmiXlllXIXfEIGfllXIGGflflGlimGGCCTC 
Hep3B 肌 謝 哪 IGflKGflGnGflmCflGflGCmGCKGCmGGflGGtKttCIflraraGGGfEGIIXQfllEniXailXKfEIGIEIGGfllEmGGCCTC 
SNU389 lira丨 GG[n[K 丨哪 IGM 丨咖棚 GCGMHGfinraCflG[丨 丨 flCCCCttGGCfllXI；丨(XIHflfllXniXIXflfllXCIKaGflCnGGflflGCmGGCCTC 
SNU398 (i 棚服 咖丨 GflKGinGfimCfl[删 K 丨[[KIXmGGIlGIXIGCCimiracaGGIllXraiKlllEniXraiEKIEIGIEIGGflflGI；而 GGCCTC 
SNU475 G 細丨GG[nCTC 丨GflCTG 抓咖側 GCGflGnGflmCfl[咖 KKCKCCK 丨GG 縦 [ K K 町 [ 丨 G f l [ C r a f l f l G ( : m G G C C T C 
H K C I - 1 GTGflTGGCTTCTCTGflCTGGflTGflCTGflGCGflGTTGflTTTCflCflGCTCTCCTCCCTCTGGflGCCTCCCCTflCCCCCCGGCflCCCTCCCCCflflCCTTCCCCflflCCCCRCCTffl 
HKCI-C1 GIGfl 孤 [ m m 隨丨 GGfllGfl[側 GGGinGflmCfl[脈丨[IGtraGmGGflGIXIIXmflracaGGCfECKIIIXfEmillXlllXIXfllX 丨 GIE 丨 GGflfEmGGCCTC 
HKCI-2 (ilG 町 GGma[ra[IGGfl 棚[丨GflGGGfiGnGflnra[亂miXKKKIGGflG[[丨[KCIflraraGOGCaiXIEflfllXniXIXfllEIXIEIGIEIGGflflGCmGGCCTC 
HKCI-3 (i 側 IGGmCK 丨賺 IGGfl 欄[IGflGCGflGnGflm[fl[flGm丨[丨 GGflGCmraiflKaKGGGflGGmKIXflfEmraiErafla：丨 GfEIGGflflGI：而 GGCCTC 
HKCM GIGfll 咖 mKIGfl[磁 fl 丨弧 IGflGCGflGnGflm �.[KKCraCKIGGflGI：!；丨[CCII 慨 QIXIEfCIXKIXIXflfllXniXrafllECIEIGflIX 丨 GGfllEmGGCCK 
HKCI-C2 GIGflIGGma(:ra[IGGflIGfl[IG 舰 GflGnGmraGflGCKraraGKIGGflGKKCffllflraKGGGCflGCGIGKrafllimiXGflfEKIEnifEIGGfllEMGGCCTC 
HKCI-C3 GIGfl 丨 GGma[丨賺磁 fl™aGflKGfiGnGmi[fl[flG[KKCra(;mGGflG[[K[[m[[Q[GG[flQK(;(:[(l(Xn[(;(:(:flfl(:(:(;(:fi(X 丨 GfETGGflfEmGGCCTC 
HKCI-7 G 欄丨 GG[n[mGOGGflIGfl[丨 GflG[GfiGnGflmCfl[flG[KraK[[KIGGflG[ara_[[[CC[GG[fl[[[丨 ra[[flfl[[n(:[(;(:iE(:(XIEIGfl(;(：丨 GGflflG[mGG[CTC 
HKCI-8 GIM服ma[丨 •丨GflGCGflGnGflmCflGflGmraKIIKIGGfEaiXmfllKraGGIEIXiraiXflfllXniXIXflfElXIEIGflGaGGfllEmGGCCK 
HKCI-9 GIGflramCKIGflC 磁fl 丨 GOGflG[GflGnGflmCfl[fiG[KI[[raaaGGflG[[ratt 丨虹[[(XGG[卩[[acraGflflCmiXIXIEIXIilEIGfllX 丨 GGflflG[mGG(:CTC 
HKCI-10 GTGflTGGCTTCTCTGflCTGGflTGflCTGflGCGflGTTGflTTTCfiCflGCTCTCCTCCCTCTGGftGCCTCCCCTflCCCCCCGGCflCCCTCCCCCflRCCTTCCCCflfiCCCCfl 
丰 
Figure 3.4.1c Alignment of ATF5 Exon 2-1 region with the reference sequence from U C S C 
database (red: >90% homology, blue: >50% and <90% homology, black: <50% homology 
when comparing with other samples). Black arrow denotes polymorphism at nucleotide 69 
according to the NCBI database. 
Lym: Lymphocytic D N A 
LN: Normal liver samples 
70 
1 10 20 30 50 GO ?0 80 90 100 110 120 130 
I- 4- 1 i • • • • 1 1 1 
ucsc flCGICiGGflCCTGCTCfllCGfiGGIITflCiGGCCCGGiCCeGflGGfiCCCGM 
Lymi flCGICflfl(lCCTGCTCflmGmflC(lflGGCCCGGflGCC(imC^^^^^ 









LN8 fl[GKflflGGfl[[EraraflGGmfl[_G[[[GGflG[[_GGfl[咖僅[IG[腦flflGEflGGGG而GG[m丨GGGGG[丨GGKn[flG〔丨i LN9 flCGICflllGGIlCCIGCICfllCGflGGnmGGCCCGGflGCM^ | 
LN10 fl[GKflflGGfl[[EK肌.Gmfl[fl_[[[GG舰[編GGflraGia町fl議GGG哪GGG滞GG[n〖_GGGaGGKn〔删 
PLCS flCGT^GGflCaGCKflKGMmflCflflGGIXCGGflGIXflGflGGfllXliGrai：丨 GCTflGflflGGGIlGGGMGGmi：丨 GGGGGaGGTCnCIEKIGGIECnCflKCCCCramma 
Huh? flCGK 瞧 GflKTGCKflraflGGmilllGGCIXGGflGIXflGflGGfiraGTfEIGaflGflfiGGGCflGGGGmGGm[丨 GGGGGI：丨 GGKmfEKTGGIECnCflTIXraraXiaflOT 丨: 
HepG2 (IGGIGflflGGIEMKflrailGGmflmGGCraGIEIlllGGfECG^ aGGIflGflflGGGGflGGGGmGGCn[咖 GGGDIGGICnCflGCK 丨 GGCGCCnCflKCC[[丨 GlXiaUCa 丨 
Hep3B fl[GICflflGGfl[aGCKflKGflGGn慨fiflGK[[GGflG[C_GGfl[[CG 側[孤•刪 GGCflGGGGIGIGGIini：側 GGGl；丨GG 丨[nCfEKIGGCIEnCIEIXIXIGCI；了ClfllXI ‘ 
S N U 3 8 9 flCGTCIIflGGflCCTGCTCflTCGflGGTTTflCflflGGCCCGGflGCCflGflGGflCCCGTflGCTGCTRGfiflGGGCflGGGGTGTGGCTTCTGGGGGCTGGTCTTCflGCTCTGGCGCCTTCflTCC ‘ 
S N U 3 9 8 flCGTCflflGGflCCTGCTCflTCGflGGmflCflflGGCCCGGflGCCflGflGGflCCCGTflGCTGCTflGflflGGGCflGGGGTGTGGCTTCTGGGGGCTGGTCTTCflGCTCTGGCGCCTTCflTCCCCCTGCCTC 
S N U 4 7 5 flCGK冊GGflCaGCKfi 丨CG^mflCflflGGCCCGGflGCCflGRGGflCCCGTflGaGCTflGflflGGGCflGGGGTGTGGCncrcGGGGI；丨GGICnCflGCK 丨GGCGCCnCflTCCCCCraXiailCa : 
H K C I - 1 [丨GQCflKG^ mflllGGIXCGGIEIlflGGIEGGIflGCnillGflflGGGCflGGGG而GGmCTflGGGGaGGTCmiEKTGGIEmCflKIXIllimm 道n “ 
HKCI.C1 flCGTCflflGGflCCTGCTCflTCGflGGTTTRCflflGGCCCGGflGCCflGflGGflCCCGTflGCTGCTBGiGGGCflGGGGTGTGGCTICIflGGGGCIGGTCnCiCTCIGG^ i! 
H K C I - 2 OOimiflGGflinGaCflrcGflGGmflCflflGGIXCGGflGCCflGflGGfllXCGIflGmCIflGflflGGGCflGGGGIGniGCnClllGGGGI：丨 GGICnCflGC 丨 a G G C G C C n C f l r a X C C r a r a f l C a 
HKCI-3 fl[GI[_Gfl[[rai[flKGflGGmfl[flflGG(:(;(:GGflG(XflGflGGfl(:(XG�flG(;ni(:™flflGGG(:flGGGGmGG[n[IflGGGG(:iGGKn(:flG[mGG(;G(Xn(:flI(:[(:(：[丨 G(XKTfl[a 
HKCI-4 fl[GKfflGGfl[[MKfl 丨咖GGmflMflGGKCGG 舰[flGflGGfl[[[GIflGm[丨flGflflGGG[_G(imGG[n[IGGGGGaGGn:n(;flG(;i(;rai(i;[�n;fln:ra;aG(:(:iaflCCI 
H K C I - C 2 flCGKflflGGfl[[MKflKGflGGn 而 flflGGIXCGGIlGCIlflGGflCCCGIfEniaflGflflGGGIlGGGIGIGGmaflGGGGI；丨 GGKniimiGGCGIXmflKIXCQGCCIl；丨 RIXI 
HKCI.C3 fl[GKflflGGfl[[mKflraflGGmfl[flflGGCCCGGflGCCflGflGGfl(:a:GIflGI：服慨(IflGGGCflGGGG丨 GIGGCm 丨 llGGGGCniGKnCIEK 丨 GGIEmCflKKCC 丨 GIXmiE 丨 
HKCI-7 flCGK 冊 GGfl[aGa[肌 GflGGmfl[_G[[[GG(IG(:i:flGflGGfE(:GIflG[丨 GIlflGflflGGGGflGGGGmGGGni：孤 GGGCIGGKnCIEiaGGIEmCfiraXIXraiiafllXI ‘ 
H K C I - 8 flCGTCflflGGfiCCTGCTCflTCGIlCGTTTflCflflGGCCCGGflGCCflGflGGflCCCGTflGCTGCTflGflflGGGCflGGGGTGTGGCTTCTIlGGGGCTGGTCTTCflGCTCTGGCGCCTTCflTCCCCCTGCCTCT^ 1. 
HKCI-9 fl[GKflflG 哪[丨GCKflraflMmraflGGCIXGGflGCllllGGfllXCG 丨lEIGaflGflfiGGGCflGGGGmGGIinCfflGGGGC 丨 GG 丨mCfEK 丨 GGCGIXnCflllECaGCCmflCCl ；  
HKCMO fl[G 丨•GGfl[[丨 GCKfl 丨[GflGGmflllGGIXGGGIEIlflGGIiraG 哪(lllGflflGGGIlGGGmGGGn[丨 IGGGGI；丨 GGKnillimGGIiGGIinmiXIXaGIX 丨 aiica 
牛 L. ...: 
Figure 3.4.Id Alignment of ATF5 Exon 2-2 region with the reference sequence from UCSC 
database (red: >90% homology, blue: >50% and <90% homology, black: <50% homology 
when comparing with other samples). Black arrow denotes polymorphism at nucleotide 84 
according to the NCBI database. 
Lym: Lymphocytic D N A 
LN: Normal liver samples 
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Hep3B 门 
2 4 O 2 5 O 2 e O 
A G A C 丁 A 丁G G G A A A C T N C C C C C G G C C C C T G <3 C C： C O C 
uliWlfvrtH 
Normal Liver 丨 
2 4 O 2 5 O 2 & O "l 
AG A C T A 丁 G G G J W A A ^ T C C C C C C G G C C C C T G C C C C C C ‘ 
iilbrtlhH^ 丨 
Figure 3.4.2 A silent mutation was identified in Hep3B. Codon CTC^'" CTT"^ '" w a s ~ 
indicated in Exon 1. 
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3.3.2 FISH Analysis of ATF5 Copy Number 
FISH analysis revealed in 11 H C C cell lines a copy number loss of the ATF5 gene. 
Representative images of the dual-labeled FISH analysis are shown in Figure 3.5. A 
concordance in copy number loss and reduced expression of ATF5 was hence suggested 
in 11/18 cell lines (61%) (Table 3-4). 
3.3.3 Epigenetic Control of ATF5 Expression 
In the 6 H C C cell lines treated with 5-Aza, re-expression of ATF5 was suggested in 
three cell lines, HKCI-Cl, HKCI-8 and Hep3B. An effect on ATF5 expression was not 
suggested in TSA treatment alone (Figure 3.6). Nevertheless, a synergistic effect of 
5-Aza and TSA was observed when cell lines were treated with both drugs. A 
re-expression of ATF5 was suggested in all cell lines (100%) in the combined treatment 
(Table 3-5). 
Further investigations on the methylatoin status of ATF5 promoter region by M S P 
indicated the absence of promoter hypermethylation in CpG island 2 in all 18 cell lines 
studied (Figure 3.7). This was substantiated by further bisulfite sequencing of CpG 
island 2 in 4 cell lines, namely HKCI-Cl, 4，5 and Hep3B (Figure 3.8). 
In the bisulfite sequencing of CpG island 1，9 cell lines (Hep3B, PLC5, Huh7, 
HKCI-1, HKCI-Cl, HKCI-C3, HKCI-4, HKCI-7 and HKCI-8) presented an increased 













































































































































































Table 3-4. FISH analysis of ATPScoyrj number loss 
…1 Reduced ATF5 Cony number 
Cell lines 
expression loss 
n~" + + 
_ 2 + ： 
丁 + + 
I + = - = I 
_7 + ： 





I C3 + -
SNU387 + + 
SNU398 + + 
SNU475 + + 
PLCS + + 
Huh7 + + 
Hep3B + -
HepG2 + + 
Expression obtained relative to a pool of normal livers 
"+" Down-regulaion of ATF5 expression 
"+丨丨 Positive for A TFJcopy loss 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Sequence analysis of ATF5, including the 5'UTR and 2 exons, did not suggest any 
mutational changes throughout the genomic sequences. Although a base change of C T C 
C T T was found in Exon 1 of Hep3B，this was later found to be a silent mutation that 
resulted in no alteration in the Leucine amino acid encoded. The present finding would 
hence suggest that mutational changes may not be a mechanism underlying ATF5 
inactivation in HCC. Similarly, a tumor suppressor gene PTEN/MMACl, which is 
commonly inactivated in cervical cancer, does not exhibit common mutations (Su et al. 
2000). Furthermore, an important oncogene, epidermal growth factor receptor (EGFR), 
described in H C C carcinogenesis, its up-regulation was also not modulated by D N A 
mutations (Su et al. 2005; Al-Kuraya et al. 2006). 
Copy number loss is a common mechanism in gene inactivation. Copy number loss 
of ATF5 was suggested in 11 cell lines, where a concordance of copy loss and 
down-regulation of ATF5 was indicated in 61% of the cases. It was reported in breast 
cancer, copy loss of BRCAl occurred in 31% of cases in which BRCAl loss correlated 
significantly with high-grade tumors (Rio et al. 1998). Moreover, in lung cancer, copy 
loss of A P C was also found to correlate with tumor progression (Sanchez Cespedes et al. 
1997). This present finding would suggest copy loss may be one of the mechanisms in 
the inactivation of ATF5 in HCC. 
Gene inactivation by epigenetic deregulation is commonly found in human cancers. 
In lung cancer, expression of PTEN was suppressed by promoter methylation, where 
PTEN m R N A expression could be induced by the treatment with the demethylating 
agent 5-Aza (Soria et al. 2002). In an effort to investigate if methylation was involved in 
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the ATF5 down-regulation, H C C cell lines were subjected to 5-Aza treatment. As shown 
in Figure 3.6 and Table 3-5, 3 H C C cell lines demonstrated restoration of ATF5 
expression after 5-Aza treatment. This might in turn suggest that promoter methylation 
might have constituted to the transcriptional regulation of ATF5 in some H C C cases. The 
methylation status of the promoter CpG islands were hence further examined by M S P 
and bisulfite sequencing. Since CpG island 2 covers ATF5 transcription start site, M S P 
was first performed to examine the methylation status of this region. The M S P results, 
however, did not suggest differential methylation status between H C C cell lines with 
normal livers and lymphocytic D N A s (Figure 3.7). This result was further confirmed 
from bisulfite sequencing (Figure 3.8). On the other hand, in the examination of CpG 
island 1, which is farther away from transcription start site, an increased methylation 
index was demonstrated in 9 cell lines compared to normal livers (Figure 3.9). This 
region that spanned from -794 to -688 harbored a number of transcription factor binding 
sites such as SPl, E-12 and NF-E2 and might hold importance in the regulation of ATF5 
expression. Furthermore, as shown in Table 3-5，histone acetylation may also be 
involved in the control ATF5 expression since the combined treatments of 5-Aza and 
T S A induced a re-expression of ATF5 in all cell lines. However, since TSA treatment 
alone did not suggest an effect in ATF5 expressions, this might imply that histone 
acetylation could only work synergistically with D N A demethylation in the control of 
ATF5 expression. This phenomenon has also been reported in the control of other 
candidate tumor suppressor genes. Suppressor of cytokines signaling 3 (SOSC-3) is a 
gene inactivated by promoter hypermethylation in HCC. In response to 5-Aza treatment, 
SOSC-3 has been shown to re-express in H C C cell lines and the level of re-expression 
could be further enhanced by the synergistic action of 5-Aza and TSA (Niwa et al. 
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2005). 
According to the 2-hit hypothesis, both alleles in a diploid cell must be silenced or 
lost so as to silence the expression of a tumor suppression gene (Nowak et al. 2004). In 
this chapter, complete copy loss of both ATF5 alleles was not found in the cell lines 
studied. Irrespective to the ploidy status，the presence of at lease one copy of the ATF5 
gene was found. The inactivation of the remaining allele by promoter hypermethylation 
of C p G island 1 might be another mechanism. When summarizing the results of 
inactivation mechanisms analysis, it can be found that 4 cell lines fulfilled the 2-hit 
hypothesis, which were HKCI-1, HKCI-8, Huh7 and PLCS. There remain a number of 
cell lines with only either one of the inactivating mechanism (12/18). This might in turn 
suggest the possibility of other inactivating mechanism or the tumor suppressive effect 
of ATF5 could be induced by haploinsufficiency. Previous study has suggested that Pten 
effect can be induced from haploinsufficiency since the transgenic Pten'' mice could 
still develop breast cancer more rapidly compared control (Li et al. 2001). If this was 
the case in ATF5, cell lines that presented one inactivating mechanism might be 
sufficient to induce the suppressive effect of ATF5 expression found in HCC. 
Furthermore, it is also noteworthy that repression of ATF5 through indirect 
transcriptional control from another transcription factor cannot be ruled out. 
To summarize, findings from this chapter suggested copy number loss and 
promoter hypermethylation as 2 likely mechanisms involved in the down-regulations of 
ATF5 in H C C . 
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Chapter 4 
Functional Examination and 
Investigation of Downstream Targets 
Modulated by ATF5 
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4.1 Introduction 
ATF5 is a member of ATF family proteins which comprise a large group of 
basic-region leucine zipper (bZIP) proteins. The ATF family members such as ATF2 and 
ATF3 are known to play a role in controlling cell cycle, cell survival and proliferation 
(Hai et al. 2001; Persengiev et al. 2003). Although it has been suggested that ATF5 plays 
an essential role in the hematopoietic cell survival and neuronal cell diferentiations 
(Angelastro et al. 2003; Angelastro et al. 2005; Mason et al. 2005), the functional role(s) 
of ATF5 in cancer development remained largely undefined. The novel identification of 
a high frequency of ATF5 down-regulations in H C C has prompted the functional 
investigation of this gene described in this chapter. 
In this study, a functional role of ATF5 on cell growth control was examined by 
ectopic expression of ATF5 on Hep3B and HKCI-Cl cells in in-vitro. The effect of 
ATF5 on tumorigenecity in-vivo was examined by xenograft development of stably 
transfected Hep3B cells with ATF5 or control vector. The effect of ATF5 on genes 
expression was examined by CodeLink microarray analysis in transient and stably 
transfected Hep3B cells with an aim to understand the modulated path way (s). Since 
global gene expression profiling will invariably generate a large number of differentially 
expressed genes, the examination of common deregulated genes found in both transient 
and stable transfected cells will aid the streamline and prioritization of downstream 
candidates. In response to ectopic expression of ATF5, genes that were consistently up-
or down-regulated by 2-fold or more in both transient and stable transfected Hep3B cells 
were defined. The data sorted were further subjected to clustering analysis and 
subsequent bioinformatics analysis revealed a number of potential pathways mediated 
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by ATF5. In an attempt to define the immediate downstream targets of ATF5，known 
genes identified were also examined for the ATF consensus binding sequence 
[TGACGT(C/A)(G/A)] (Hai et al. 2001) in the promoter region. 
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4.2 Materials and Methods 
4.2.1 Cell Lines 
H C C cell lines, Hep3B and HKCI-Cl, were cultured according the method 
described in Section 2.11.1. Cell growth effect from transient ATF5 transfection in 
Hep3B and HKCI-Cl were studied, while transient and stably transfected Hep3B cells 
were further investigated in microarray analysis. 
4.2.2 Plasmids and Transfection 
Plasmids were constructed and transfected into Hep3B cells or HKCI-Cl cells 
according to Section 2.11.1. The re-expression of ATF5 was confirmed by QRT-PCR. 
4.2.3 Cell Growth Assay 
Twenty-four hours after transfection, Hep3B and HKCI-Cl cells were seeded onto 
a 96-well culture panel and the cell proliferation rate was measured by M T T assays 
according to the procedure described in Section 2.11.2. 
4.2.4 Xenograft Development 
Stably transfected Hep3B cells were cultured according to section 2.11.1. The 
Hep3B cells transfected with ATF5 or control vector were subjected to xenograft 
development according to the procedure described in section 2.11.3. 
88 
4.2.5 CodeLink Expression Microarray 
After transient transfection for 48hr with control pcDNA3.1 or pcDNA3.1-^7F5, 
total R N A from Hep3B cells was extracted. The stably transfected Hep3B clone was 
cultured according to procedure described in Section 2.11.1. Total R N A from transient 
and stable transfections were subjected to cRNA synthesis and hybridization to the 
CodeLink UniSet Human 20K I Bioarray according to the procedure mentioned in 
Section 2.12. The hybridized bioarray was then scanned by the GenePix 4000B scanner 
and analyzed by CodeLink Expression Analysis software v.4. The expression fold 
change greater than 2 or less than 0.5 was regarded as differential expression. By 
comparing the microarray results of stable and transient transfection, genes that were 
up-regulated or down-regulated in both transfections were selected. Supervised 
hierarchical clustering was performed by the Cluster software package 
(http://rana.lbl.gov/EisenSoftware.htrrO (Eisen et al. 1998) and the cluster generated was 
converted to graphic presentation by the Treeview software 
(http://rana.lbl.gov/EisenSoftware.htm) (Eisen et al. 1998). Potential molecular 
pathways modulated by ATF5 were investigated through bioinformatics analysis using 
the OntoExpress and Pathway Express Software (Draghici et al. 2003) based on the 
information available from Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathway database. Furthermore, few genes containing the ATF consensus binding 
sequence in the promoter region were identified, amongst which Id-1 was further 
validated by QRT-PCR. 
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4.2.6 Quantitative RT-PCR 
The expression of ATF5 and Id-1 in Hep3B cells before and after transfection was 
first examined to confirm array findings. Subsequent investigation of ATF5 expressions 
in correlation with Id-1 transcription was carried out in 29 primary H C C and 5 H C C cell 
lines including Hep3B, SNU398, SNU475, HKCI-C2 and HKCI-8. The Taqman PCR 
was performed according to the procedure described in Section 2.10. Primers and probes 
for 18s (Hs99999901_sl) and ATF5 (Hs00247172_ml) were acquired from Applied 
Biosystems. Primers for Id-1 were (sense) 5’-CTC TAG G A C ATG A A C G G C T G T T-3' 
(antisense) 5'-TGC T C A C C T T G C G G T TCT G-3' and the probe for Id-1 was 5,-CAC 
G C C T C A A G G A G C T G G T G C C-3，(Lee et al. 2003). 
4.2.7 Statistical analysis 
Paired Student's t-test was applied to compare the differences between the relative 
growth of cells transfected with vector alone and vector containing ATF5 clone. 
Pearson's correlation was used to examine the correlation between ATF5 and Id-1 
m R N A expression. A difference in growth rate or correlation in expressions were 
considered significant if a p-value achieved was less than 0.05. All the statistical analysis 
were performed by Graphpad Prism 3.0. 
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4.3 Results 
4.3.1 Cell Proliferation 
4.3.1.1 In- Vitro Examination 
Transient transfection of Hep3B cells and HKCI-Cl cells with pcDNA3.1-^7F5 
showed significant suppression in cell proliferation by 30% and 45% respectively when 
compared to pcDNA3.1 control vector (Figure 4.1a, 4.1b). These results were in 
concordance with the effect observed in the stably transfected Hep3B clone with ATF J 
(Figure 4.1c), which showed a 50% growth inhibitory effect. 
4.3.1.2 In- Vivo Examination 
Effect of ATF5 on tumor growth was examined in in-vivo model. Stably transfected 
Hep3B cells were used in xenograft development. After a month of xenograft 
development, a delay in xenograft development was suggested, where tumor volume of 
ATF5 transfected Hep3B cells was much smaller compared to control vector transfected 
Hep3B (Figure 4.2). 
4.3.2 Microarray Analysis 
The effect of ATF5 on the transcriptional changes of Hep3B was investigated by 
expression microarray. In response to ATF5 ectopic expression, 2339 genes and 340 
genes were up-regulated by 2-fold or more in the transient and stable transfection of 
Hep3B cells, respectively. Within those up-regulated genes, 57 genes showed consistent 
up-regulations in both transient and stable transfected cells. On the other hand, 55 
commonly down-regulated genes were indicated from 2424 and 286 down-regulated 
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genes in the Hep3B transient and stable transfections, respectively (Figure 4.3). 
Supervised hierarchical clustering analysis of the microarray data (57 up-regulated and 
55 down-regulated genes) revealed discrete cluster dendrograms of ATF5 transfected 
cells and control vector. Among the 112 candidates, 29 known genes exhibited 
distinctive differential gene expression levels (Figure 4.4). Thirteen of them were 
up-regulated and 16 down-regulated genes. The information of the 29 known genes have 
been listed in Table 4-1. Bioinformatics analysis of the 112 genes revealed several 
pathways that may be modulated by ATF5. Differentially expressed genes involved 
included focal adhesion, M A P kinase signaling and regulation of actin cytoskeleton 
pathways were suggested (Table 4-2). 
In an effort to elucidate for the potential immediate downstream targets of ATF5, 
sequence of the promoter region (2kb upstream from 5'UTR) of the 29 known genes 
was examined for the presence of the ATF consensus binding site [TGACGT(C/A)(G/A)] 
(Hai et al. 2001). Based on information obtained from the UCSC database, 4 genes were 
found including tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein ( Y W H A H ) , dual specificity phosphatase 1 (DUSPl), inhibitor of differentiation 
or DNA binding 1 (Id-1) and RAS viral oncogene homolog (RRAS) contained the ATF 
consensus binding sequence in the proximity of the promoter region. The ATF consensus 
binding sequence of 2 genes, Id-1 and RRAS, were located before the transcription start 
site at -826bp and -1.6kb respectively. The remaining 2 genes, Y W H A H and DUSPl, 
however were located after the transcription start site at +71 bp and +46bp respectively. 
The induction level for each gene in response to ATF5 transfection is shown in Table 
4-1. 
Since the ATF consensus binding site of Id-1 was the closest to the transcription 
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start site, this gene was further investigated in correlation with ATF5 expressions. 
C o m m o n over-expression of Id-1 has been reported in H C C (Lee et al. 2003; Matsuda et 
al. 2005) and a functional importance of Id-1 in cell growth control has been suggested 
(Ouyang et al. 2002). The differential Id-1 expression derived from microarray analysis 
was further validated by QRT-PCR. A down-regulation of Id-1 in response to either 
transient or stable transfection of ATF5 in Hep3B cells was confirmed (Figure 4.5). 
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Figure 4.1 ATF5 expression showed significant cell growth inhibition in Hep3B and 
HKCI-Cl cell lines 
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Hep3B cells transfected Hep3B cells stably 
with control vector expressing ATF5 
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Figure 4.2 A suppression in tumorigenecity was suggested in stably transfected Hep3B 
xenograft 
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Figure 4.3 Altered genes expression in response to ATF5 ectopic expression in 
Hep3B. (A). Genes that were up-regulated after transfection with^rFJ. (B). Genes 
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Figure 4 5 In response to ATF5 ectopic expression, a reduction in Id-1 expression by 
〜50O/O was suggested compared to vector control in both transient and stable 
transfections 
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4.3.3 Correlation of ATF5 with Id-1 expressions 
Id-1 expression in 29 primary HCC and 5 HCC cell lines were examined. Id-1 
was consistently up-regulated in all HCC cell lines (from 2 to more than 100-fold) 
and in 31% (9/29) of primary HCC examined (from 2 to 6-fold) (Figure 4.6). The 
m R N A expression level of ATF5 was found to inversely correlate with that of Id-1 








































































































































































































































































































































































































































































































































i P e a r s o n r = -0.399 
2n P = 0.019 
I i � — f : -3 • » 
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- 2 - 1 0 1 2 3 4 
Log(10) ld-1 
gure 4.7 Correlation between ATF5 and Id-1 expressions. ATF5 expression was 
gnificantly correlated with Id-1 m R N A level (p=0.019). An inverse correlation with 
I r-value of -0.399 was suggested. 
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4.4 Discussion 
In this chapter, a functional role of ATF5 in affecting HCC cell growth was 
demonstrated. Ectopic expression of ATF5 resulted in a growth inhibition in both 
Hep3B and HKCI-Cl cells (Figure 4.1). Furthermore, a suppression in 
tumorigenecity was suggested in ATF5 stably transfected Hep3B xenograft compared 
to control vector (Figure 4.2). The ATF5 modulated pathway(s) were further 
investigated by microarray analysis. Through the application of OntoExpress and 
Pathway Express software, 3 pathways were suggested that might be under the 
transcriptional control of ATF5. These being the focal adhesion, M A P K signaling 
pathway and regulation of actin cytoskeleton. Of interest was that the EGFR and 
RRAS genes were found to be involved in all 3 pathways. 
EGFR over-expression has been described in 60-70% of HCC cases and its 
up-regulation has been suggested to play an important role in tumor development and 
progression (Ito et al. 2001; Liu et al. 2006). Common EGFR over-expressions can 
be found not only in HCC, but also in lung cancer, ovarian cancer and breast cancer 
(Verbeek et al. 1998; Nielsen et al. 2004; Kawai et al. 2005). Once epidermal growth 
factor bind to EGFR, signal transduction pathways such as M A P K signaling pathway 
can be activated. As a result, gene(s) that involved in growth induction can be 
transcribed. In this thesis, when ATF5 was transfected into Hep3B cells, EGFR 
expression was down-regulated and so growth induced suppression through the 
inactivation of EGFR pathway might have occurred. This might in turn imply that 
ATF5 might have suppressed HCC cell growth and tumorigenecity through the 
inhibition of M A P K signaling pathway via EGFR down-regulation. 
RRAS belongs to Ras family of small GTPases. It is well recognized that Ras 
signaling pathway is involved in the regulation of cellular transformation and cell 
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growth (Ching et al. 2003; Leung et al. 2005). Previous study had demonstrated that 
RRAS has an oncogenic role on promoting cell growth from ectopic expression in 
cervical epithelial cells (Rincon-Arano et al. 2003). It was found in this chapter that 
RRAS expression was down-regulated upon ATF5 ectopic expression. A direct 
growth inhibitory effect of ATF5 through the RRAS signaling pathway might be a 
possible mechanism. Since ATF consensus binding sequence was found in the 
promoter region of RRAS’ albeit at 1.6kb from the transcription start site, its 
expression might be directly regulated by ATF5. 
Although Y W H A H and DUSPl contain the ATF consensus binding sequence, 
these sites were found to locate after the transcription start site. Id-1, on the other 
hand, present the ATF consensus binding site closest to the transcription start site and 
hence was further investigated in this thesis. QRT-PCR confirmed the 
down-regulation of Id-1 gene in Hep3B cells after ATF5 transfections (Figure 4.5). 
Furthermore, statistical analysis of ATF5 and Id-1 expressions in a cohort of 29 HCC 
tumors demonstrated an inverse correlation between their expressions (r-0.399; 
p=0.019) (Figure 4.7). This might imply that Id-1 could be likely a downstream 
target of ATF5. Id-1 belongs to the helix-loop-helix (HLH) transcription factor family 
(Ling et al. 2002b). Since Id-1 does not contain a highly basic D N A binding domain 
that recognizes specific D N A region in the promoter-enhancer of genes (Tournay et 
al. 1996; Massari et al. 2000), it therefore serves as a dominant negative regulator of 
bHLH transcription factor (Norton 2000; Ling et al. 2002a; Ling et al. 2002b). That 
means once a transcription factor form hetero-dimer with Id-1, the activity of the 
transcription factor will be suppressed. 
Id-1 can regulate cell differentiation, cell survival, immortalization and 
senescence (Desprez et al. 1995; Matsuda et al. 2005). It has been reported that Id-1 
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is commonly over-expressed in 38-60% of HCC (Lee et al. 2003; Matsuda et al. 
2005). Other cancers also demonstrate Id-1 up-regulation such as prostate cancer 
(Ouyang et al. 2002; Coppe et al. 2004; Ling et al. 2005), breast cancer (Lin et al. 
2000; Fong et al. 2003; Schoppmann et al. 2003), pancreatic cancer (Maruyama et al. 
1999), cervical cancer (Schindl et al. 2001), head & neck cancer (Langlands et al. 
2000), melanomas (Polsky et al. 2001). In HCC, Id-1 has been suggested to induce 
cell proliferation through pl6腿4a inactivation (Lee et al. 2003; Matsuda et al. 
2005). The transcription of pi6腿4a tumor suppressor gene is induced by Ets-1 and 
Ets-2 protein that contain HLH domain. Id-1 binds to Ets-1 and Ets-2, which can in 
turn inhibit their transcriptional activity for pi6觀a expression. Without pl6i腿a 
expression, cyclin D1 can activate CDK4 which will phosphorylate pRB and releases 
E2F. As a result, activated E2F protein can initiate S-phase gene transcription and 
allow G1 to S phase conversion (Weintraub et al. 1992; Kato et al. 1993; Lee et al. 
2003; Oikawa et al. 2003). It is possible that loss of ATF5 expression in HCC can 
result in up-regulation of Id-1 and subsequent uncontrolled transcriptional activities. 
Furthermore, previous study has suggested that ectopic Id-1 expression can 
activate the Raf/MEKl/2 signaling pathway. When M A P K signaling pathway was 
inhibited through the inhibition ofMEKl/2 phosphorylation, Id-1 can reduce prostate 
cancer cell growth. It implied that Id-1 might regulate cell growth through the 
association with M A P K signaling pathway (Ling et al. 2002a). From the 
bioinformatics analysis, the Focal Adhesion and Actin Cytoskeleton pathways found 
in this thesis are also involved in the M A P K signaling pathway. This may suggest 
that M A P K signaling pathway may be the most important pathway involved in the 
cellular control of ATF5. M A P K signaling pathway is one of the important pathways 
involved in activation of cell proliferation. This pathway is highly activated in a 
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number of cancers such as HCC (Huynh et al. 2003), colon cancer (Darmoul et al. 
2004), gastric cancer (Husain et al. 2001) and prostate cancer (Tessier et al. 2001). In 
HCC, over-expression of proteins participating in M A P K signaling pathway, such as 
MEKl/2 and ERKl/2, was observed in >90% of the cases (Schmidt et al. 1997; 
Huynh et al. 2003). When the EGFR receives mitogen signal, M A P K ERKs will be 
activated and translocate to the nucleus. Activated ERKs will then phosphorylate 
different transcription factors, such as Etsl and c-MYC, to activate transcription of 
genes that can promote cell growth, differentiation or mitosis (Stokoe et al. 1994). 
Since M A P K signaling pathway plays an important role in cell proliferation and 
differentiation, critical importance of M A P K over-expression has been inferred in 
H C C development (Schmidt et al. 1997) and hence might in turn suggest a 
significant role of ATF5 in HCC carcinogenesis. 
Previous study has also demonstrated that ATF5 could increase sensitivity to 
cisplatin-induced apoptosis through the induction of Cyclin D3 (CCND3) 
transcription in Hela cells (Wei et al. 2006). However, in our study, ATF5 was instead 
found to suppress CCND3 expression in HCC cells (Table 4-1). This might suggest 
that the functional pathways modulated by ATF5 might differ in different cancer 
types and thus the elucidation on the mechanistic role of ATF5 in HCC warrants 




Proposed Future Investigations 
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5.1 Inactivation Mechanisms of ATF5 Gene 
In Chapter 3 of this thesis, inactivation mechanisms of ATF5 gene were 
investigated. About 60% of the HCC cell lines studied showed copy number loss 
from FISH analysis and half of the cases showed promoter hypermethylation from 
bisulfite sequencing analysis. These findings suggested that copy number loss and 
promoter hypermethylation were 2 possible mechanisms underlying the 
down-regulation ofATFS in HCC. 
Of particular interest was the re-expression of ATF5 in all cell lines were 
indicated from the combinatorial treatment of 5-Aza and TSA. This might potentially 
underlie therapeutic potentials for HCC patients as analogues of 5-Aza and TSA for 
clinical use are currently available. 
The combinatorial effect of Zebularine and SAHA in in-vivo HCC xenograft 
models can be first examined for the re-expression of ATF5 and suppression of tumor 
growth. Although 5'Aza is a very potent D N A methylation inhibitor, it has a high 
cytotoxicity and is unstable in circulation. On the other hand, Zebularine, another 
D N A demethylating agent, presents less toxicity and is relatively stable. Zebularine 
has an approximately 508hr half-life at pH7.0 which makes oral administration of it 
possible. In-vitw analysis also suggested cancer cell lines could uptake this drug at a 
higher rate than normal fibroblasts (Yoo et al. 2004a). For the H D A C inhibitor, 
S A H A can be considered in the in-vivo study instead of TSA since Phase I and Phase 
II clinical trials of SAHA has already shown that it is a promising anticancer drug. In 
addition, when administered orally, bioavailability of SAHA is also good (Coradini et 
al. 2005; Uchida et al. 2005)(Kumar et al. 2004). Nevertheless, it is also known 
demethylating agent lacks specificity and so genes that were normally silenced by 
methylation may also be re-activated (Worm et al. 2002). Therefore, effect of 
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combinatorial treatment ofZebularine and SAHA in in-vivo needs careful monitoring 
in order to determine the drugs efficacy. 
5.2 Molecular Pathways Modulated by ATF5 
Functional role of ATF5 on cell viability and tumorigenecity was indicated in 
the present study. Previously study has suggested an interaction between ATF5 and 
CCND3 where CCND3 is a gene involved in G1 to S phase cell cycle control 
(Menges et al. 2006). Further examination of ATF5 in controlling cell cycle could 
include flow cytometry analysis and BrdU incorporation assay for the investigation 
of growth rate. 
Microarray analysis indicated a number of possible pathways modulated by 
ATF5 and potential downstream target Id-1 was further confirmed to inversely 
correlate with ATF5 expressions. Since Id-1 over-expressions have been reported to 
hold importance in cancer developments, the further understanding of the 
transcriptional control of Id-1 expressions should shed insight into liver 
carcinogenesis. In order to confirm interaction of Id-1 with ATF5, luciferase assay 
and gel shift assay could be carried out in future investigations. Gel shift assay can 
demonstrate whether or not ATF5 can bind to the promoter region of Id-1 and 
luciferase promoter assay can reveal if ATF5 can increase the transcriptional activity 
of Id-J. 
It is due to the lack of a reliable source of ATF5 and Id-1 antibodies that the 
protein levels of Id-1 and ATF5 cannot be examined in this thesis. However, this is 
an important aspect in understanding the interaction between these 2 proteins. Future 
development can consider custom-made antibodies from Zymed Laboratories INC. 
Furthermore, investigations on interacting partner(s) of ATF5 can be carried out by 
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pull-down assay followed promoter assay analysis, which should provide valuable 
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